XENOPORT INC 424B5, filed Jul 8, 2009: 424B5
Table of Contents
CALCULATION
OF REGISTRATION FEE
|
Proposed |
||||||||||||||||
|
Maximum |
Proposed Maximum |
|||||||||||||||
|
Amount To Be |
Offering Price |
Aggregate Offering |
Amount Of |
|||||||||||||
| Title of Each Class of Securities To Be Registered | Registered | Per Unit | Price | Registration Fee | ||||||||||||
|
Common Stock, $0.001 par value per share, including related
rights to purchase Series A Junior Participating Preferred
Stock(1)
|
2,875,000 | (2) | $ | 19.00 | $ | 54,625,000.00 | $ | 3,048.08 | (3) | |||||||
(1) Each share of the Registrant’s common stock that
is registered hereunder, if issued prior to the termination by
the Registrant of its rights agreement, dated as of
December 15, 2005, includes Series A junior
participating preferred stock purchase rights. Prior to the
occurrence of certain events, the Series A junior
participating preferred stock purchase rights will not be
exercisable or evidenced separately from the Registrant’s
common stock and have no value except as reflected in the market
price of the shares to which they are attached.
(2) Includes 375,000 shares that the underwriters have
the option to purchase to cover over-allotments, if any.
(3) The filing fee is calculated and being paid pursuant to
Rule 457(r) under the Securities Act of 1933, as amended,
and relates to the Registration Statement on
Form S-3
(File
No. 333-156485)
filed by the Registrant on December 30, 2008.
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-156485
Registration No. 333-156485
PROSPECTUS SUPPLEMENT
(To Prospectus dated December 30, 2008)
Issued July 8, 2009
(To Prospectus dated December 30, 2008)
Issued July 8, 2009
2,500,000 Shares
Common Stock
XenoPort, Inc. is offering 2,500,000 shares of its common
stock.
Our common stock is listed on The NASDAQ Global Select Market
under the symbol “XNPT.” On July 7, 2009, the
last reported sale price of our common stock on The NASDAQ
Global Select Market was $21.50 per share.
Investing in our common stock involves significant risks. See
“Risk Factors” beginning on
page S-6.
Price $19.00 Per Share
|
Underwriting |
||||||||||||
|
Price to |
Discounts and |
Proceeds to |
||||||||||
| Public | Commissions | XenoPort | ||||||||||
|
Per Share
|
$ | 19.0000 | $ | 1.0925 | $ | 17.9075 | ||||||
|
Total
|
$ | 47,500,000 | $ | 2,731,250 | $ | 44,768,750 | ||||||
We have granted the underwriters a
30-day
option to purchase up to an aggregate of 375,000 additional
shares of common stock on the same terms as set forth above. See
the section of this prospectus supplement entitled
“Underwriters.”
The Securities and Exchange Commission and state securities
regulators have not approved or disapproved these securities, or
determined if this prospectus supplement or the accompanying
prospectus is truthful or complete. Any representation to the
contrary is a criminal offense.
The underwriters expect to deliver the shares of common stock to
purchasers on or about July 13, 2009.
| Morgan Stanley | Goldman, Sachs & Co. |
July 8, 2009
TABLE OF
CONTENTS
Prospectus
Supplement
| Page | ||||
| S-ii | ||||
| S-1 | ||||
| S-6 | ||||
| S-28 | ||||
| S-29 | ||||
| S-30 | ||||
| S-31 | ||||
| S-32 | ||||
| S-35 | ||||
| S-39 | ||||
| S-39 | ||||
| S-39 | ||||
Prospectus
| Page | ||||
|
About This Prospectus
|
2 | |||
|
Risk Factors
|
3 | |||
|
Special Note Regarding Forward-Looking Statements
|
3 | |||
|
Use of Proceeds
|
4 | |||
|
Description of Capital Stock
|
4 | |||
|
Description of Warrants
|
7 | |||
|
Description of Units
|
9 | |||
|
Validity of Capital Stock
|
10 | |||
|
Experts
|
10 | |||
|
Where You Can Find More Information
|
10 | |||
No dealer, salesperson or other person is authorized to give any
information or to represent anything not contained in this
prospectus supplement or the accompanying prospectus. You must
not rely on any unauthorized information or representations.
This prospectus supplement and the accompanying prospectus are
an offer to sell only the shares offered hereby, but only under
circumstances and in jurisdictions where it is lawful to do so.
The information contained in this prospectus supplement and the
accompanying prospectus is current only as of their respective
dates.
Table of Contents
ABOUT
THIS PROSPECTUS SUPPLEMENT
This document is in two parts. The first part is this prospectus
supplement, which describes the specific terms of the common
stock we are offering and also adds to and updates information
contained in the accompanying prospectus and the documents
incorporated by reference into this prospectus supplement and
the accompanying prospectus. The second part, the accompanying
prospectus dated December 30, 2008, including the documents
incorporated by reference, provides more general information.
Generally, when we refer to this prospectus, we are referring to
both parts of this document combined. To the extent there is a
conflict between the information contained in this prospectus
supplement, on the one hand, and the information contained in
the accompanying prospectus or in any document incorporated by
reference that was filed with the Securities and Exchange
Commission, or SEC, before the date of this prospectus
supplement, on the other hand, you should rely on the
information in this prospectus supplement. If any statement in
one of these documents is inconsistent with a statement in
another document having a later date — for example, a
document incorporated by reference in the accompanying
prospectus — the statement in the document having the
later date modifies or supersedes the earlier statement. You
should read this prospectus supplement and the accompanying
prospectus, including the information incorporated by reference
and any free writing prospectus that we have authorized for use
in connection with this offering, in their entirety before
making an investment decision.
You should rely only on the information contained or
incorporated by reference in this prospectus supplement and the
accompanying prospectus, along with the information contained in
any free writing prospectus that we have authorized for use in
connection with this offering. If the description of the
offering varies between this prospectus supplement and the
accompanying prospectus, you should rely on the information in
this prospectus supplement. We have not authorized anyone to
provide you with different or additional information. You should
assume that the information appearing in this prospectus
supplement, the accompanying prospectus, the documents
incorporated by reference in this prospectus supplement and the
accompanying prospectus, and any free writing prospectus that we
have authorized for use in connection with this offering is
accurate only as of the respective dates of those documents. Our
business, financial condition, results of operations and
prospects may have changed since those dates.
S-ii
Table of Contents
PROSPECTUS
SUPPLEMENT SUMMARY
This summary highlights selected information appearing
elsewhere or incorporated by reference in this prospectus
supplement and the accompanying prospectus, and may not contain
all of the information that is important to you. This prospectus
supplement and the accompanying prospectus include information
about the shares of common stock that we are offering as well as
information regarding our business. You should read this
prospectus supplement and the accompanying prospectus, including
the information incorporated by reference and any free writing
prospectus that we have authorized for use in connection with
this offering, in their entirety. Investors should carefully
consider the information set forth under “Risk
Factors” in this prospectus supplement before making your
investment decision.
XenoPort,
Inc.
Overview
We are a biopharmaceutical company focused on developing a
portfolio of internally discovered product candidates that
utilize the body’s natural nutrient transport mechanisms to
improve the therapeutic benefits of existing drugs. We are
currently focusing our development and commercialization efforts
on potential treatments of central nervous system, or CNS,
disorders.
We are developing our lead product candidate, XP13512, in
partnership with Astellas Pharma Inc. and Glaxo Group Limited,
or GSK. The U.S. Food and Drug Administration, or FDA, has
accepted for review a new drug application, or NDA, that was
submitted by GSK for approval to market XP13512, also known as
GSK1838262 (gabapentin enacarbil), in the United States for the
treatment of moderate-to-severe primary restless legs syndrome,
or RLS. RLS is a common, under-diagnosed neurological condition
that frequently manifests itself as a sleep disorder. GSK is
also evaluating XP13512 for the potential treatment of
post-herpetic neuralgia, or PHN, painful diabetic neuropathy, or
PDN, and migraine prophylaxis. Astellas is evaluating XP13512,
which is known as ASP8825 in the Astellas territory, in Japan as
a potential treatment for RLS. We are evaluating our second
product candidate, XP19986, for the potential treatment of
gastroesophageal reflux disease, or GERD, spasticity in patients
with spinal cord injury and acute back spasms of musculoskeletal
origin. We are evaluating our third product candidate, XP21279,
for the potential treatment of Parkinson’s disease.
Each of our product candidates is an orally available, patented
or patentable new chemical entity addressing large potential
markets. Our innovative product candidates, which we refer to as
Transported Prodrugs, are created by modifying the chemical
structure of currently marketed drugs, referred to as parent
drugs, and are designed to correct deficiencies in the oral
absorption, distribution
and/or
metabolism of the parent drug. Our proprietary technology
utilizes the body’s natural mechanisms for actively
transporting nutrients through cellular barriers to permit
certain parent drugs with suboptimal oral absorption to be
effectively and efficiently delivered into the body after oral
administration of our product candidates.
A key component of our strategy is to reduce the risks and time
associated with drug development by capitalizing on the known
safety, efficacy and established drug development history of the
parent drugs. Our product candidates are designed to be
metabolized to release the parent drugs and natural substances
with favorable safety characteristics. We believe that these
features will increase the probability of successfully
developing our product candidates. In addition, we intend to
seek approval of our product candidates in indications for which
the parent drugs have not been approved, but are nevertheless
used by physicians after having demonstrated efficacy in
clinical trials. We believe that the improved characteristics of
our product candidates will provide meaningful therapeutic
benefits compared to existing drugs, as well as allow for
approval to market in indications for which the parent drugs are
not currently approved or promoted.
We plan to enter into agreements with pharmaceutical companies:
(1) when access to a primary care physician sales force is
necessary to maximize the commercial potential of our product
candidates in the United States; (2) for the development
and commercialization of our product candidates outside the
United States; or (3) to develop and commercialize product
candidates that fall outside our therapeutic areas of interest.
To date, we have entered into two separate agreements for the
development and commercialization of XP13512. In December 2005,
we entered into an agreement in which we licensed to Astellas
exclusive rights to develop and commercialize XP13512 in Japan,
Korea, the Philippines, Indonesia, Thailand and Taiwan
(collectively referred to as the Astellas territory). In
S-1
Table of Contents
February 2007, we announced an exclusive collaboration with GSK
to develop and commercialize XP13512 in all countries of the
world other than the Astellas territory. We have licensed to
Xanodyne Pharmaceuticals, Inc. exclusive rights to develop and
commercialize another of our product candidates, XP21510, in the
United States, including for the potential treatment of women
diagnosed with menorrhagia, or heavy menstrual bleeding. In
March 2009, Xanodyne provided us with written notice that it has
elected to terminate the agreement. Such termination will be
effective July 22, 2009, at which time, all XP21510 product
rights will revert to us.
Our
Product Candidates
Our current portfolio of proprietary product candidates includes
the following:
XP13512. XP13512 is a Transported Prodrug of
gabapentin. We have licensed to Astellas exclusive rights to
develop and commercialize XP13512 in the Astellas territory and
have an exclusive collaboration with GSK to develop and
commercialize XP13512 in all countries of the world other than
the Astellas territory. Pursuant to the terms of our
collaboration with GSK, in April 2009, we exercised the option
to co-promote and share profits and losses from potential future
sales of XP13512 in the United States. Assuming FDA approval of
the XP13512 NDA for RLS, we plan to field a U.S. sales
force of between 50 and 100 representatives to promote XP13512.
| • | XP13512 for RLS. XP13512 has been evaluated for the treatment of RLS in a Phase 3 clinical program in the United States and in a Phase 2 clinical trial in Japan. RLS is characterized by an irresistible urge to move one’s legs, usually accompanied by unpleasant sensations or pain in the legs. We have announced top-line data from three RLS Phase 3 clinical trials that demonstrated statistically significant improvements compared to placebo on the primary endpoints of these trials and that XP13512 was generally well-tolerated. GSK has also initiated a Phase 3b polysomnography clinical trial of XP13512 to evaluate the potential sleep benefits of XP13512 in patients with RLS. The FDA is currently reviewing the NDA that was submitted by GSK for approval to market XP13512 in the United States for the treatment of moderate-to-severe primary RLS. In addition, Astellas has completed a 12-week, double-blind, placebo-controlled Phase 2 clinical trial of XP13512 for the treatment of symptoms of RLS in patients in Japan that demonstrated statistically significant improvements compared to placebo on the primary endpoint of the trial and that XP13512 was generally well-tolerated. | |
| • | XP13512 for Neuropathic Pain. Neuropathic pain results from injury to nerve fibers creating pain at the site of injury and areas around the injury. We have shown in a Phase 2a clinical trial that XP13512 improved clinical endpoints associated with PHN, a chronic type of neuropathic pain that can follow the resolution of shingles. In April 2009, GSK completed a 14-week, double-blind, placebo-controlled Phase 2 clinical trial of XP13512 as a potential treatment for PDN (also known as neuropathic pain associated with diabetic peripheral neuropathy). Neither XP13512 nor pregabalin, the active control, demonstrated a statistically significant improvement on the primary endpoint when compared to placebo in this trial. XP13512 was generally well-tolerated. GSK is also evaluating the safety and efficacy of XP13512 in the management of PHN in a Phase 2 clinical trial. | |
| • | XP13512 for Migraine Prophylaxis. Migraine is a neurological disorder characterized by recurrent headache attacks that are usually accompanied by various combinations of symptoms, including nausea and vomiting, as well as distorted vision and sensitivity to light and sound. Migraine prophylaxis treatment is designed to reduce the frequency and severity of migraine attacks. GSK is conducting a Phase 2 clinical trial designed to evaluate the safety and efficacy of XP13512 as a potential prophylactic therapy for migraine headaches. |
XP19986. XP19986, also known as arbaclofen
placarbil, is a Transported Prodrug of R-baclofen. We have
retained all rights to this product candidate.
| • | XP19986 for GERD. We are evaluating XP19986 for the potential treatment of GERD, a digestive system disorder caused primarily by transient relaxations of the lower esophageal sphincter, or LES, which is a combination of muscles that controls the junction between the esophagus and the stomach. An abnormally functioning LES can allow stomach contents to pass back into the esophagus too easily, which can result in discomfort and potential damage to the lining of the esophagus. In December 2008, we announced top-line results from a Phase 2 clinical trial that examined the ability of XP19986 to reduce symptoms experienced by |
S-2
Table of Contents
| patients with GERD. The primary analysis of this trial, which included GERD patients who had been treated with proton pump inhibitors, or PPIs, previously (PPI Experienced) as well as patients who had not been treated with PPIs previously, did not reach statistical significance. In pre-defined secondary analyses of the PPI Experienced patients, XP19986 showed improvement over placebo in several measures of symptom relief. XP19986 was generally well-tolerated at all dose levels. |
| • | XP19986 for Spasticity. We are developing XP19986 as a potential treatment for spasticity, a condition in which certain muscles are continuously contracted, interfering with movement or speech. Racemic baclofen, which contains both R-baclofen and S-baclofen, is currently approved in the United States for the treatment of spasticity resulting from multiple sclerosis, spinal cord injury and other spinal cord diseases. We believe that spasticity patients may benefit from XP19986 due to less frequent dosing and a more desirable pharmacokinetic profile than racemic baclofen. In June 2009, we announced preliminary results from a randomized, double-blind, placebo-controlled, crossover Phase 2 clinical trial of XP19986 in spinal cord injury patients with spasticity. Doses of 20 and 30 mg of XP19986, given twice daily, demonstrated statistically significant improvements compared to placebo for the primary endpoint of the trial. XP19986 was well tolerated during the trial. | |
| • | XP19986 for Acute Back Spasms. We are evaluating XP19986 as a potential treatment for the relief of discomfort from painful musculoskeletal conditions associated with acute back spasms, which are involuntary and, frequently, painful contractions of the muscles of the lower back. We are conducting an exploratory Phase 2 clinical trial of XP19986 in patients with acute back spasms of neuromuscular origin. The primary objective of this trial is to evaluate the safety and tolerability of XP19986. |
XP21279. XP21279 is a Transported Prodrug of
levodopa, or L-Dopa, that we are developing as a potential
treatment of Parkinson’s disease, a neurological disorder
of the elderly, characterized by tremor, rigidity and loss of
reflexes. In February 2009, we announced positive results from a
second Phase 1 clinical trial with two different
sustained-release formulations of XP21279 that demonstrated that
the formulations of XP21279 produced a more sustained exposure
of L-Dopa compared to oral L-Dopa dosed in the same healthy
subjects and that XP21279 was well-tolerated. We have retained
all rights to this product candidate.
XP21510. XP21510 is a Transported Prodrug of
tranexamic acid. Tranexamic acid is a man-made derivative of the
naturally occurring amino acid lysine and works to inhibit, on a
molecular basis, the breakdown of blood clots. It is approved in
many countries in Europe and Asia for the treatment of women
with menorrhagia, or heavy menstrual bleeding. Our exclusive
license to Xanodyne to develop and commercialize XP21510 in the
United States, including for the potential treatment of women
diagnosed with menorrhagia, will terminate effective
July 22, 2009, at which time, all XP21510 product rights
will revert to us.
Risks
Related to Our Business
Our business is subject to a number of risks of which you should
be aware before making an investment decision. These risks are
discussed more fully in “Risk Factors.” For example:
| • | We have incurred cumulative operating losses since inception, we expect to continue to incur losses for the foreseeable future and we may never sustain profitability. | |
| • | Our success depends substantially on our most advanced product candidates, which are still under development. If we or our collaborative partners are unable to bring any or all of these product candidates to market, or experience significant delays in doing so, our ability to generate product revenue and our likelihood of success will be harmed. | |
| • | If we or our partners are not able to obtain required regulatory approvals, we or our partners will not be able to commercialize our product candidates, our ability to generate revenue will be materially impaired and our business will not be successful. | |
| • | We depend on collaborations to complete the development and commercialization of some of our product candidates. |
S-3
Table of Contents
Company
Information
We were incorporated in Delaware in May 1999. Our principal
offices are located at 3410 Central Expressway,
Santa Clara, California 95051, and our telephone number is
(408) 616-7200.
Our website address is www.XenoPort.com. Information found on,
or accessible through, our website is not a part of, and is not
incorporated into, this prospectus supplement or the
accompanying prospectus. XENOPORT, the XenoPort logo and
Transported Prodrug are our trademarks. Service marks,
trademarks and trade names included or incorporated by reference
in this prospectus supplement or the accompanying prospectus are
the property of their respective owners. Unless the context
requires otherwise, references in this prospectus supplement and
the accompanying prospectus to “XenoPort,” “the
company,” “we,” “us” and
“our” refer to XenoPort, Inc.
S-4
Table of Contents
The
Offering
| Common stock offered by XenoPort | 2,500,000 shares | |
| Common stock to be outstanding immediately after this offering | 29,810,755 shares | |
| Use of proceeds | We currently expect to use the net proceeds from this offering for general corporate purposes, including clinical trial, research and development, general and administrative and manufacturing expenses, as well as for potential sales and marketing activities. We may also use a portion of the proceeds for the potential acquisition of, or investment in, companies, products or technologies that complement our business. See “Use of Proceeds” on page S-29. | |
| Risk factors | See “Risk Factors” beginning on page S-6 for a discussion of factors you should consider carefully before making an investment decision. | |
| NASDAQ Global Select Market symbol | XNPT |
The number of shares of our common stock to be outstanding
immediately after this offering is based on
27,310,755 shares of common stock outstanding as of
March 31, 2009 and excludes:
| • | 3,832,952 shares of our common stock issuable upon the exercise of options outstanding as of March 31, 2009, having a weighted-average exercise price of $27.73 per share; | |
| • | 290,099 shares of our common stock issuable upon the vesting of restricted stock unit awards outstanding as of March 31, 2009; | |
| • | 304,752 shares of our common stock issuable upon the exercise of warrants outstanding as of March 31, 2009, having a weighted-average exercise price of $24.95 per share; and | |
| • | an aggregate of 2,045,222 shares of our common stock reserved for future issuance as of March 31, 2009 under our 2005 Equity Incentive Plan, our 2005 Non-Employee Directors’ Stock Option Plan and our 2005 Employee Stock Purchase Plan. |
Unless otherwise indicated, the information throughout this
prospectus supplement assumes no exercise by the underwriters of
their option to purchase up to an aggregate of 375,000
additional shares of common stock in this offering.
S-5
Table of Contents
RISK
FACTORS
Investing in our common stock involves a high degree of risk.
You should carefully consider the risks described below together
with all of the other information contained or incorporated by
reference in this prospectus supplement and the accompanying
prospectus when making an investment decision. If any of the
following risks occur, the trading price of our common stock
could decline and you may lose all or part of your
investment.
Risks
Related to Our Business and Industry
We
have incurred cumulative operating losses since inception, we
expect to continue to incur losses for the foreseeable future
and we may never sustain profitability.
We have a limited operating history and have incurred cumulative
losses of $241.3 million from our inception in May 1999
through March 31, 2009. In the three months ended March 31,
2009 and 2008, we incurred net losses of $2.7 million and
$7.3 million, respectively. Due to the recognition of
revenues from up-front and milestone payments from our
collaborations with Glaxo Group Limited, or GSK, Astellas Pharma
Inc. and Xanodyne Pharmaceuticals, Inc., we were profitable in
the three-month periods ended June 30, September 30 and
December 31, 2007, and for the year ended December 31,
2007. However, while recognition of these revenues resulted in a
profitable year for 2007, we incurred net losses in 2008, and we
continue to expect to incur net losses in 2009. We expect our
research and development expenses to remain relatively constant
with 2008 levels for the next two years. Subject to regulatory
approval of any of our product candidates, we expect to incur
significant expenses associated with the establishment of a
North American specialty sales force. Annual losses have had,
and will continue to have, an adverse effect on our
stockholders’ equity.
Because of the numerous risks and uncertainties associated with
drug development, we are unable to predict the timing or amount
of increased expenses or when, or if, we will be able to achieve
or sustain profitability. Currently, we have no products
approved for commercial sale and, to date, we have not generated
any product revenues. We have financed our operations primarily
through the sale of equity securities, non-equity payments from
collaborative partners, capital lease and equipment financings
and government grants. We have devoted substantially all of our
efforts to research and development, including clinical trials.
If we or our collaborative partners are unable to develop and
commercialize any of our product candidates, if development is
delayed or if sales revenue from any product candidate that
receives marketing approval is insufficient, we may never become
profitable. Even if we do become profitable, we may not be able
to sustain or increase our profitability on a quarterly or
annual basis.
Our
success depends substantially on our most advanced product
candidates, which are still under development. If we or our
collaborative partners are unable to bring any or all of these
product candidates to market, or experience significant delays
in doing so, our ability to generate product revenue and our
likelihood of success will be harmed.
Our ability to generate product revenue in the future will
depend heavily on the successful development and
commercialization of our product candidates. In March 2009, the
U.S. Food and Drug Administration, or FDA, accepted for
review GSK’s new drug application, or NDA, requesting
approval of XP13512 (gabapentin enacarbil) for the treatment of
moderate-to-severe primary restless legs syndrome, or RLS.
XP13512 has been evaluated in a Phase 3 clinical program for RLS
in the United States and a Phase 2 clinical trial for RLS in
Japan and is being evaluated in Phase 2 clinical trials for
neuropathic pain and migraine prophylaxis in the United States.
Our other product candidates are either in Phase 1 or Phase 2
clinical development or in various stages of preclinical
development. Any of our product candidates could be unsuccessful
if it:
| • | does not demonstrate acceptable safety and efficacy in preclinical studies or clinical trials or otherwise does not meet applicable regulatory standards for approval; | |
| • | does not offer therapeutic or other improvements over existing or future drugs used to treat the same conditions; | |
| • | is not capable of being produced in commercial quantities at acceptable costs; or | |
| • | is not accepted in the medical community and by third-party payors. |
S-6
Table of Contents
We do not expect any of our current product candidates to be
commercially available before the end of 2009, if at all. If we
or our collaborative partners are unable to make our product
candidates commercially available, we will not generate
substantial product revenues and we will not be successful. The
results of our clinical trials to date do not provide assurance
that acceptable efficacy or safety will be shown upon completion
of future clinical trials.
If we
or our partners are not able to obtain required regulatory
approvals, we or our partners will not be able to commercialize
our product candidates, our ability to generate revenue will be
materially impaired and our business will not be
successful.
Our product candidates and the activities associated with their
development and commercialization are subject to comprehensive
regulation by the FDA and other agencies in the United States
and by comparable authorities in other countries. In February
2007, we announced an exclusive collaboration with GSK to
develop and commercialize XP13512, also known as ASP8825 in
Japan, Korea, the Philippines, Indonesia, Thailand and Taiwan
(collectively referred to as the Astellas territory) and by the
designation GSK1838262 outside the Astellas territory, for the
treatment of moderate-to-severe primary RLS, in all countries of
the world other than the Astellas territory. Pursuant to the
terms of our agreement, GSK submitted to the FDA an NDA
requesting approval of XP13512 for the treatment of
moderate-to-severe primary RLS and GSK will lead the development
and registration of XP13512 for all indications in GSK’s
licensed territory. The inability to obtain FDA approval or
approval from comparable authorities in other countries would
prevent us and our collaborative partners from commercializing
our product candidates in the United States or other countries.
We or our collaborative partners may never receive regulatory
approval for the commercial sale of any of our product
candidates. Moreover, if the FDA requires that any of our
product candidates be scheduled by the U.S. Drug
Enforcement Agency, or DEA, we or our collaborative partners
will be unable to begin commercial sale of that product until
the DEA completes scheduling proceedings. If any of our product
candidates is classified as a controlled substance by the DEA,
we or our collaborative partners would have to register annually
with the DEA and those product candidates would be subject to
additional regulation.
Neither we nor our collaborative partners have received
regulatory approval to market any of our product candidates in
any jurisdiction. We have only limited experience in preparing
and filing the applications necessary to gain regulatory
approvals. The process of applying for regulatory approval is
expensive, often takes many years and can vary substantially
based upon the type, complexity and novelty of the product
candidates involved. The application process begins with the
submission of an NDA that the FDA initially reviews and either
accepts or rejects for filing. NDA submissions are complex
electronic filings, which include vast compilations of data
sets, integrated documents and data calculations. The FDA has
substantial discretion in the submission process and may refuse
to accept an NDA submission if there are errors or omissions
relating to the electronic transmittal process, data entry, data
compilation or formatting. For example, in November 2008, GSK
withdrew a previously submitted NDA for XP13512 for the
treatment of moderate-to-severe primary RLS in connection with
the FDA’s request that the data from a single study be
reformatted. The NDA for XP13512 was resubmitted in January
2009, and the FDA accepted the NDA for review in March 2009.
Changes in the regulatory approval policy during the development
period, changes in, or the enactment of additional, regulations
or statutes or changes in regulatory review for each submitted
product application may cause delays in the approval or
rejection of an NDA. For example, in 2008, the FDA announced
that, due to staffing and resource limitations, it has given its
managers discretion to miss certain timing goals for completing
reviews of NDAs set forth under the Prescription Drug User Fee
Act, or PDUFA. If the FDA were to miss a PDUFA timing goal for
one of our product candidates, the development and
commercialization of the product candidate could be delayed or
impaired. In addition, the Food and Drug Administration
Amendments Act of 2007, or FDAAA, mandates FDA advisory
committee reviews of all new molecular entities as part of the
NDA approval process, although the FDA maintains discretion
under the FDAAA to approve NDAs for new molecular entities
without advisory committee reviews in certain instances. XP13512
is classified as a new molecular entity. The advisory committee
review process can be a lengthy and uncertain process that could
delay the FDA’s NDA approval and delay or impair the
development and commercialization of our product candidates.
The FDA has substantial discretion in the approval process and
may refuse to approve any application or decide that our or our
collaborative partners’ data is insufficient for approval
and require additional preclinical, clinical or other studies.
For example, varying interpretations of the data obtained from
preclinical and clinical
S-7
Table of Contents
testing could delay, limit or prevent regulatory approval of any
of our product candidates. Even if the FDA or other regulatory
agency approves a product candidate, the approval may impose
significant restrictions on the indicated uses, conditions for
use, labeling, advertising, promotion, marketing
and/or
production of such product and may impose ongoing requirements
for post-approval studies, including additional research and
development and clinical trials. The FDA and other agencies also
may impose various civil or criminal sanctions for failure to
comply with regulatory requirements, including withdrawal of
product approval.
We and our collaborative partners will need to obtain regulatory
approval from authorities in foreign countries to market our
product candidates in those countries. Approval by one
regulatory authority does not ensure approval by regulatory
authorities in other jurisdictions. If we or our collaborative
partners fail to obtain approvals from foreign jurisdictions,
the geographic market for our product candidates would be
limited.
We
depend on collaborations to complete the development and
commercialization of some of our product candidates. These
collaborations may place the development of our product
candidates outside our control, may require us to relinquish
important rights or may otherwise be on terms unfavorable to
us.
In December 2005, we entered into a collaboration with Astellas
for the development and commercialization of XP13512 in the
Astellas territory. In February 2007, we entered into an
exclusive collaboration with GSK to develop and commercialize
XP13512 worldwide, excluding the Astellas territory. In October
2007, we entered into a collaboration with Xanodyne for the
development and commercialization of XP21510 in the United
States. In March 2009, Xanodyne provided us with written notice
that Xanodyne has elected to terminate the collaboration
agreement, which termination will be effective on July 22,
2009.
We may enter into additional collaborations with third parties
to develop and commercialize some of our product candidates. Our
dependence on Astellas and GSK for the development and
commercialization of XP13512 subjects us to, and our dependence
on future collaborators for development and commercialization of
additional product candidates will subject us to, a number of
risks, including:
| • | we may not be able to control the amount and timing of resources that our collaborators may devote to the development or commercialization of product candidates or to their marketing and distribution; | |
| • | collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; | |
| • | disputes may arise between us and our collaborators that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management’s attention and resources; | |
| • | collaborators may experience financial difficulties; | |
| • | collaborators may not be successful in their efforts to obtain regulatory approvals in a timely manner, or at all; | |
| • | collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation; | |
| • | business combinations or significant changes in a collaborator’s business strategy may also adversely affect a collaborator’s willingness or ability to complete its obligations under any arrangement; | |
| • | a collaborator could independently move forward with a competing product candidate developed either independently or in collaboration with others, including our competitors; and | |
| • | the collaborations may be terminated or allowed to expire, which would delay the development and may increase the cost of developing our product candidates. |
For example, we cannot control the process for securing FDA
approval of XP13512 for moderate-to-severe primary RLS. We
cannot control the amount and timing of resources that GSK or
Astellas may devote to the
S-8
Table of Contents
development or commercialization of XP13512 or its marketing and
distribution. In addition, GSK or Astellas could independently
direct their respective development and marketing resources to
the development or commercialization of competitive products,
which could delay or impair the commercialization of XP13512 and
harm our business.
If we
do not establish collaborations for our product candidates other
than XP13512, we will have to alter our development and
commercialization plans.
Our strategy includes selectively collaborating with leading
pharmaceutical and biotechnology companies to assist us in
furthering development and potential commercialization of some
of our product candidates. We intend to do so especially for
indications that involve a large, primary care market that must
be served by large sales and marketing organizations. We face
significant competition in seeking appropriate collaborators,
and these collaborations are complex and time consuming to
negotiate and document. We may not be able to negotiate
additional collaborations on acceptable terms, or at all. We are
unable to predict when, if ever, we will enter into any
additional collaborations because of the numerous risks and
uncertainties associated with establishing additional
collaborations. If we are unable to negotiate additional
collaborations, we may have to curtail the development of a
particular product candidate, reduce or delay its development
program or one or more of our other development programs, delay
its potential commercialization or reduce the scope of our sales
or marketing activities or increase our expenditures and
undertake development or commercialization activities at our own
expense. If we elect to increase our expenditures to fund
development or commercialization activities on our own, we may
need to obtain additional capital, which may not be available to
us on acceptable terms, or at all. If we do not have sufficient
funds, we will not be able to bring our product candidates to
market and generate product revenues.
We
will need additional funding and may be unable to raise capital
when needed, which would force us to delay, reduce or eliminate
our product development programs or commercialization
efforts.
We will need to raise additional capital to fund our operations
and complete the development of our product candidates. If any
product candidates receive regulatory approval for commercial
sale, we may need to raise additional capital to fund our
commercialization efforts. Our future funding requirements will
depend on many factors, including:
| • | the scope, rate of progress, results and cost of our preclinical testing, clinical trials and other research and development activities; | |
| • | the timing of potential receipt of FDA approval of XP13512 and its potential commercialization; | |
| • | the cost of manufacturing clinical, and establishing commercial, supplies of our product candidates and any products that we may develop; | |
| • | the timing of any milestone payments under our collaborative arrangements; | |
| • | the number and characteristics of product candidates that we pursue; | |
| • | the cost, timing and outcomes of regulatory approvals; | |
| • | the cost and timing of establishing sales, marketing and distribution capabilities; | |
| • | the terms and timing of any collaborative, licensing and other arrangements that we may establish; | |
| • | the timing, receipt and amount of sales, profit sharing or royalties, if any, from our potential products; | |
| • | the cost of preparing, filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and | |
| • | the extent to which we acquire or invest in businesses, products or technologies, although we currently have no commitments or agreements relating to any of these types of transactions. |
Until we can generate a sufficient amount of product revenues,
if ever, we expect to finance future cash needs through public
or private equity offerings, debt financings or corporate
collaboration and licensing arrangements, as well as through
interest income earned on cash balances. However, the credit
markets and the financial services
S-9
Table of Contents
industry have recently been experiencing a period of unusual
turmoil and upheaval characterized by the bankruptcy, failure,
collapse or sale of various financial institutions and an
unprecedented level of intervention from the U.S. federal
government. These events have generally made equity and debt
financing more difficult to obtain.
If we raise additional funds by issuing equity securities, our
stockholders may experience dilution. Any debt financing or
additional equity that we raise may contain terms that are not
favorable to our stockholders or us. To the extent that we raise
additional capital through licensing arrangements or
arrangements with collaborative partners, we may be required to
relinquish, on terms that are not favorable to us, rights to
some of our technologies or product candidates that we would
otherwise seek to develop or commercialize ourselves.
We believe that our existing capital resources and expected
milestone payments, together with interest thereon, and the net
proceeds from this offering will be sufficient to meet our
projected operating requirements into the third quarter of 2011.
We have based this estimate on assumptions that may prove to be
wrong, and we could utilize our available capital resources
sooner than we currently expect. Further, our operating plan may
change, and we may need additional funds to meet operational
needs and capital requirements for product development and
commercialization sooner than planned. We currently have no
credit facility or committed sources of capital other than
potential milestones receivable under our current
collaborations. If this offering is not completed, we believe
that we have sufficient funds to meet our projected operating
requirements into the second quarter of 2011.
Additional funds may not be available when we need them on terms
that are acceptable to us, or at all. If adequate funds are not
available on a timely basis, we may:
| • | terminate or delay clinical trials for one or more of our product candidates; | |
| • | delay our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize our product candidates; | |
| • | curtail significant drug development programs that are designed to identify new product candidates; or | |
| • | at any time upon advance notice to GSK, exercise the right to revert to a net sales royalty-based compensation structure and forego the right to co-promote XP13512 in the United States. |
For example, in January 2009, we suspended preclinical
development activities for XP20925, our Transported Prodrug of
propofol, to focus our resources on development of later-stage
product candidates.
If our
preclinical studies do not produce successful results or our
clinical trials do not demonstrate safety and efficacy in
humans, we will not be able to commercialize our product
candidates.
To obtain the requisite regulatory approvals to market and sell
any of our product candidates, we must demonstrate, through
extensive preclinical studies and clinical trials, that the
product candidate is safe and effective in humans. Preclinical
and clinical testing is expensive, can take many years and has
an uncertain outcome. A failure of one or more of our clinical
trials could occur at any stage of testing. For example, in
April 2009, GSK completed a 14-week, double-blind,
placebo-controlled, Phase 2 clinical trial of XP13512 as a
potential treatment for painful diabetic neuropathy, or PDN, in
which neither XP13512 nor pregabalin, the active control,
demonstrated a statistically significant improvement on the
primary endpoint when compared to placebo. In addition, success
in preclinical testing and early clinical trials does not ensure
that later clinical trials will be successful, and interim
results of a clinical trial do not necessarily predict final
results. We may experience numerous unforeseen events during, or
as a result of, preclinical testing and the clinical trial
process, which could delay or prevent our or our collaborative
partners’ ability to commercialize our product candidates,
including:
| • | regulators or institutional review boards may not authorize us to commence a clinical trial at a prospective trial site; | |
| • | our preclinical testing or clinical trials may produce negative or inconclusive results, which may require us to conduct additional preclinical or clinical testing or to abandon projects that we expect to be promising; | |
| • | we may suspend or terminate our clinical trials if the participating patients are being exposed to unacceptable health risks; |
S-10
Table of Contents
| • | risks associated with clinical trial design may result in a failure of the clinical trial to show statistically significant results even if the product candidate is effective; | |
| • | regulators or institutional review boards may suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements; and | |
| • | the effects of our product candidates may not be the desired effects or may include undesirable side effects. |
As an example of an unforeseen event, after having been
discharged from a Phase 1 clinical trial in which a single dose
of XP13512 was administered almost two days earlier, a volunteer
died of a self-inflicted gunshot wound following a domestic
dispute. We do not believe that this incident was related to
XP13512. However, any unforeseen event could cause us to
experience significant delays in, or the termination of,
clinical trials. Any such events would increase our costs and
could delay or prevent our ability to commercialize our product
candidates, which would adversely impact our financial results.
Any
failure or delay in commencing or completing clinical trials for
our product candidates could severely harm our
business.
The commencement and completion of clinical trials for our
product candidates may be delayed or terminated as a result of
many factors, including:
| • | delays in patient enrollment, which we have experienced in the past, and variability in the number and types of patients available for clinical trials; | |
| • | our inability or the inability of our collaborators or licensees to manufacture or obtain from third parties materials sufficient for use in preclinical studies and clinical trials; | |
| • | difficulty in maintaining contact with patients after treatment, resulting in incomplete data; | |
| • | poor effectiveness of product candidates during clinical trials; | |
| • | unforeseen safety issues or side effects; and | |
| • | governmental or regulatory delays and changes in regulatory requirements, policy and guidelines. |
For example, based on the results of a planned interim analysis
of the clinical data, although no safety concerns were noted,
Astellas terminated its Phase 2 clinical trial of XP13512 as a
potential treatment for PDN due to difficulty in demonstrating a
statistically significant advantage of XP13512 over placebo
under the current clinical trial design. Any delay in commencing
or completing clinical trials for our product candidates would
delay commercialization of our product candidates and severely
harm our business and financial condition. In addition,
unforeseen safety issues or side effects could result from our
collaborators’ current or future clinical trials, which
could delay or negatively impact commercialization of our
product candidates. It is also possible that none of our product
candidates will complete clinical trials in any of the markets
in which we or our collaborators intend to sell those product
candidates. Accordingly, we or our collaborators would not
receive the regulatory approvals needed to market our product
candidates, which would severely harm our business and financial
condition.
We
rely on third parties to conduct our clinical trials. If these
third parties do not perform as contractually required or
expected, we may not be able to obtain regulatory approval for,
or commercialize, our product candidates.
We do not have the ability to independently conduct clinical
trials for our product candidates, and we must rely on third
parties, such as contract research organizations, medical
institutions, clinical investigators, collaborative partners and
contract laboratories, to conduct our clinical trials. We have,
in the ordinary course of business, entered into agreements with
these third parties. Nonetheless, with the exception of XP13512
outside the United States for RLS and all other indications
around the world, we are responsible for confirming that each of
our clinical trials is conducted in accordance with its general
investigational plan and protocol. Moreover, the FDA requires us
to comply with regulations and standards, commonly referred to
as good clinical practices, for conducting and recording and
reporting the results of clinical trials to assure that data and
reported results are credible and accurate and that the trial
participants are adequately protected. Our reliance on third
parties that we do not control does not
S-11
Table of Contents
relieve us of these responsibilities and requirements. For
example, we need to prepare, and ensure our compliance with,
various procedures required under good clinical practices, even
though third-party contract research organizations have prepared
and are complying with their own, comparable procedures. If
these third parties do not successfully carry out their
contractual duties or regulatory obligations or meet expected
deadlines, if the third parties need to be replaced or if the
quality or accuracy of the data they obtain is compromised due
to the failure to adhere to our clinical protocols or regulatory
requirements or for other reasons, our preclinical development
activities or clinical trials may be extended, delayed,
suspended or terminated, and we may not be able to obtain
regulatory approval for, or successfully commercialize, our
product candidates.
If
some or all of our patents expire, are invalidated or are
unenforceable, or if some or all of our patent applications do
not yield issued patents or yield patents with narrow claims,
competitors may develop competing products using our
intellectual property and our business will
suffer.
Our success will depend in part on our ability to obtain and
maintain patent and trade secret protection for our technologies
and product candidates both in the United States and other
countries. We have a number of U.S. and foreign patents,
patent applications and rights to patents related to our
compounds, product candidates and technology, but we cannot
guarantee that issued patents will be enforceable or that
pending or future patent applications will result in issued
patents. Alternatively, a third party may successfully
circumvent our patents. Our rights under any issued patents may
not provide us with sufficient protection against competitive
products or otherwise cover commercially valuable products or
processes.
The degree of future protection for our proprietary technologies
and product candidates is uncertain because legal means afford
only limited protection and may not adequately protect our
rights or permit us to gain or keep our competitive advantage.
For example:
| • | we might not have been the first to make the inventions covered by each of our pending patent applications and issued patents; | |
| • | we might not have been the first to file patent applications for these inventions; | |
| • | others may independently develop similar or alternative technologies or duplicate any of our technologies; | |
| • | it is possible that none of our pending patent applications will result in issued patents; | |
| • | any patents issued to us or our collaborators may not provide a basis for commercially viable products or may be challenged by third parties; or | |
| • | the patents of others may have an adverse effect on our ability to do business. |
Even if valid and enforceable patents cover our product
candidates and technologies, the patents will provide protection
only for a limited amount of time.
Our and our collaborators’ ability to obtain patents is
highly uncertain because, to date, some legal principles remain
unresolved, there has not been a consistent policy regarding the
breadth or interpretation of claims allowed in patents in the
United States and the specific content of patents and patent
applications that are necessary to support and interpret patent
claims is highly uncertain due to the complex nature of the
relevant legal, scientific and factual issues. Furthermore, the
policies governing biotechnology patents outside the United
States are even more uncertain. Changes in either patent laws or
interpretations of patent laws in the United States and other
countries may diminish the value of our intellectual property or
narrow the scope of our patent protection.
Even if patents are issued regarding our product candidates or
methods of using them, those patents can be challenged by our
competitors who can argue such patents are invalid
and/or
unenforceable. For example, in September 2008, a law firm on
behalf of an undisclosed client filed an opposition against the
patent grant of one of our European patent applications covering
XP13512, and in April 2009, we filed a response to the
opposition. Unlike in the United States, where an issued patent
is presumed valid, third parties in Europe have nine months
following the grant of a patent in which to file an opposition
during which there is no presumption of patent validity.
Accordingly, the grant of the European patent will be subject to
a full review. While we cannot predict the duration or result of
this opposition proceeding, a corresponding U.S. patent was
issued, and the most important of the prior
S-12
Table of Contents
art that was cited in the European opposition as a basis for
challenging the issuance of the European patent covering XP13512
was cited to the European Patent Office during the prosecution
of that European patent. The possible revocation of the European
patent or amendment of its granted claims would not preclude us
from developing and commercializing XP13512 in Europe, but could
increase the risk of competition. Patents also may not protect
our product candidates if competitors devise ways of making
these or similar product candidates without legally infringing
our patents. The Federal Food, Drug and Cosmetic Act and FDA
regulations and policies provide incentives to manufacturers to
challenge patent validity and these same types of incentives
encourage manufacturers to submit NDAs that rely on literature
and clinical data not prepared for or by the drug sponsor.
Subject to possible patent term extension, the entitlement for
which and the term of which we cannot predict, patent protection
in the United States covering XP13512, our product candidate
that is a Transported Prodrug of gabapentin, will expire no
earlier than 2022. We believe that in all countries in which we
hold or have licensed rights to patents or patent applications
related to XP13512, the composition-of-matter patents relating
to gabapentin have expired. For XP19986, our product candidate
that is a Transported Prodrug of R-baclofen,
U.S. composition-of-matter patents have issued that will
expire no earlier than 2025. For XP21279, our product candidate
that is a Transported Prodrug of L-dopa, a
U.S. composition-of-matter patent has issued that will
expire no earlier than 2025. For XP21510, our product candidate
that is a Transported Prodrug of tranexamic acid, a
U.S. composition-of-matter patent has issued that will
expire no earlier than 2026. Although third parties may
challenge our rights to, or the scope or validity of, our
patents, to date, other than the European opposition described
above, we have not received any communications from third
parties challenging our patents or patent applications covering
our product candidates.
We may obtain patents for certain product candidates many years
before marketing approval is obtained for those products.
Because patents have a limited life, which may begin to run
prior to the commercial sale of the related product, the
commercial value of the patent may be limited. However, we may
be able to apply for patent term extensions.
As part of the approval process of our product candidates in the
United States, the FDA may determine that the product candidates
be granted an exclusivity period during which other
manufacturers’ applications for approval of generic
versions of our products will not be granted. Generic
manufacturers often wait to challenge the patents protecting
products that have been granted exclusivity until one year prior
to the end of the exclusivity period. While the FDA has
historically granted a five-year new chemical entity exclusivity
to prodrugs such as XP13512 and XP19986, a law suit was recently
filed by a generic drug company against the FDA challenging the
grant of the
five-year
exclusivity to another company’s prodrug. If such a suit
against the FDA is successful, it could mean that XP13512 and
XP19986 receive shorter or no exclusivity periods. It is also
possible that generic manufacturers are considering attempts to
seek FDA approval for a similar or identical drug as our product
candidate through an abbreviated NDA, which is the application
form typically used by manufacturers seeking approval of a
generic drug. If our patents are subject to challenges, we may
need to spend significant resources to defend such challenges
and we may not be able to defend our patents successfully.
We also rely on trade secrets to protect our technology,
especially where we do not believe that patent protection is
appropriate or obtainable. However, trade secrets are difficult
to protect. Our employees, consultants, contractors, outside
scientific collaborators and other advisors may unintentionally
or willfully disclose our confidential information to
competitors. Enforcing a claim that a third party illegally
obtained and is using our trade secrets is expensive and
time-consuming, and the outcome is unpredictable. Failure to
obtain or maintain trade secret protection could adversely
affect our competitive business position.
Our research and development collaborators may have rights to
publish data and other information in which we have rights. In
addition, we sometimes engage individuals or entities to conduct
research that may be relevant to our business. The ability of
these individuals or entities to publish or otherwise publicly
disclose data and other information generated during the course
of their research is subject to certain contractual limitations.
In most cases, these individuals or entities are, at the least,
precluded from publicly disclosing our confidential information
and are only allowed to disclose other data or information
generated during the course of the research after we have been
afforded an opportunity to consider whether patent
and/or other
proprietary protection should be sought. If we do not apply for
patent protection prior to such publication or if we cannot
otherwise maintain the confidentiality of our
S-13
Table of Contents
technology and other confidential information, then our ability
to receive patent protection or protect our proprietary
information may be jeopardized.
Third-party
claims of intellectual property infringement would require us to
spend significant time and money and could prevent us from
developing or commercializing our products.
Our commercial success depends in part on not infringing the
patents and proprietary rights of other parties and not
breaching any licenses that we have entered into with regard to
our technologies and products. Because others may have filed,
and in the future are likely to file, patent applications
covering products or other technologies of interest to us that
are similar or identical to ours, patent applications or issued
patents of others may have priority over our patent applications
or issued patents. For example, we are aware of a family of
third-party patent applications relating to prodrugs of
gabapentin. We believe the applications have been abandoned in
the United States, the European Patent Office, Canada,
Australia and the United Kingdom. Additionally, we are aware of
third-party patents relating to the use of baclofen in the
treatment of gastroesophageal reflux disease, or GERD. If the
patents are determined to be valid and construed to cover
XP19986, the development and commercialization of XP19986 could
be affected. With respect to the claims contained in these
patent applications and patents, we believe that our activities
do not infringe the patents at issue
and/or that
the third-party patent or patent applications are invalid.
However, it is possible that a judge or jury will disagree with
our conclusions regarding non-infringement
and/or
invalidity, and we could incur substantial costs in litigation
if we are required to defend against patent suits brought by
third parties or if we initiate these suits. Any legal action
against our collaborators or us claiming damages and seeking to
enjoin commercial activities relating to the affected products
and processes could, in addition to subjecting us to potential
liability for damages, require our collaborators or us to obtain
a license to continue to manufacture or market the affected
products and processes. Licenses required under any of these
patents may not be available on commercially acceptable terms,
if at all. Failure to obtain such licenses could materially and
adversely affect our ability to develop, commercialize and sell
our product candidates. We believe that there may continue to be
significant litigation in the biotechnology and pharmaceutical
industry regarding patent and other intellectual property
rights. If we become involved in litigation, it could consume a
substantial portion of our management and financial resources
and we may not prevail in any such litigation.
Furthermore, our commercial success will depend, in part, on our
ability to continue to conduct research to identify additional
product candidates in current indications of interest or
opportunities in other indications. Some of these activities may
involve the use of genes, gene products, screening technologies
and other research tools that are covered by third-party
patents. Court decisions have indicated that the exemption from
patent infringement afforded by 35 U.S.C. § 271(e)(1)
does not encompass all research and development activities
associated with product development. In some instances, we may
be required to obtain licenses to such third-party patents to
conduct our research and development activities, including
activities that may have already occurred. It is not known
whether any license required under any of these patents would be
made available on commercially acceptable terms, if at all.
Failure to obtain such licenses could materially and adversely
affect our ability to maintain a pipeline of potential product
candidates and to bring new products to market. If we are
required to defend against patent suits brought by third parties
relating to third-party patents that may be relevant to our
research activities, or if we initiate such suits, we could
incur substantial costs in litigation. Moreover, an adverse
result from any legal action in which we are involved could
subject us to damages
and/or
prevent us from conducting some of our research and development
activities.
If
third parties do not manufacture our product candidates in
sufficient quantities or at an acceptable cost, clinical
development and commercialization of our product candidates
would be delayed.
We do not currently own or operate manufacturing facilities for
the production of clinical or commercial quantities of any of
our product candidates. To date, we have relied on, and we
expect to continue to rely on, a limited number of third-party
compound manufacturers and active pharmaceutical ingredient, or
API, formulators for the production of preclinical, clinical and
commercial quantities of our product candidates. We do not have
commercial supply agreements with any of these third parties,
and our agreements with these parties are generally terminable
at will by either party at any time. If, for any reason, these
third parties are unable or unwilling to perform under our
agreements or enter into new agreements, we may not be able to
locate alternative manufacturers or
S-14
Table of Contents
formulators or enter into favorable agreements with them. Any
inability to acquire sufficient quantities of our product
candidates in a timely manner from these third parties could
delay clinical trials and prevent us or our partners from
developing and commercializing our product candidates in a
cost-effective manner or on a timely basis.
Under the terms of our collaboration with GSK, GSK is solely
responsible for the manufacture of XP13512 to support its
development and commercialization within its licensed territory.
As a result, if GSK fails to manufacture sufficient quantities
of XP13512, development and commercialization of this product
candidate could be impaired or delayed in the GSK licensed
territory. In addition, we are responsible for providing
Astellas both clinical and commercial supplies of XP13512 API.
Thus, we expect to continue to rely on a limited number of
third-party manufacturers to meet our clinical and commercial
supply obligations to Astellas for XP13512 API. We purchase
substantial amounts of gabapentin, which is used to make
XP13512, from Teva Pharmaceutical Industries, Ltd. pursuant to
purchase orders issued from time to time. Teva’s sale of
gabapentin is the subject of ongoing litigation brought by
Pfizer Inc alleging infringement of a patent held by Pfizer. In
2007, the Court of Appeals for the Federal Circuit overturned a
2006 District Court ruling that was in favor of the generic
gabapentin makers, including Teva, and the suit has been
remanded to the District Court to continue with the trial. We
have also recently qualified two additional potential suppliers
of gabapentin, Hikal Ltd. and Divis Laboratories Ltd. In the
event that Teva or these additional suppliers decides not to
sell gabapentin to us, or decides to sell gabapentin to us at a
price that is not commercially attractive, or, as a result of
this litigation, ceases producing gabapentin, we would not be
able to manufacture XP13512 until an alternative supplier was
qualified. This could impair our ability to meet our supply
obligations to Astellas and delay their ability to commercialize
this product candidate.
We currently rely on Lonza Ltd. as the single source supplier of
our current requirements of XP13512 API. We have agreed to
purchase XP13512 API from Lonza under a manufacturing services
and product supply agreement. In the event that Lonza terminates
the agreement in response to a breach by us, we would not be
able to manufacture the API until a qualified alternative
supplier is identified. This could delay the development of, and
impair the ability of us or Astellas to commercialize, this
product candidate. In addition, our current agreement with Lonza
does not provide for the entire supply of API that we require to
support Astellas’ full-scale commercialization. However,
the manufacturing services and product supply agreement
obligates the parties to negotiate in good faith on the terms
and conditions for Lonza to supply some or all of our total
requirements for the commercial supply of XP13512 API. In the
event that the parties cannot agree to the terms and conditions
for Lonza to provide some or all of our API commercial supply
needs, we would not be able to manufacture API until a qualified
alternative supplier is identified. This could impair our
ability to satisfy our contractual obligations to Astellas and
could also delay or impair Astellas’ ability to develop and
commercialize XP13512. Unless earlier terminated, our current
agreement with Lonza expires in July 2010.
We currently rely on Excella GmbH (formerly Heumann Pharma GmbH)
as our single source supplier of R-baclofen, the active agent
used to make XP19986, under purchase orders issued from time to
time. We are aware of two alternative suppliers of R-baclofen,
and we are in the process of qualifying them as alternative
suppliers. In the event that Excella determines to not sell
R-baclofen to us at a price that is commercially attractive, and
if we were unable to qualify an alternative supplier of
R-baclofen, this could delay the development of, and impair our
ability to commercialize, this product candidate.
We currently rely on Lonza as the single source supplier of our
current worldwide requirements of XP19986 in API form under a
manufacturing services and product supply agreement. Our current
agreement with Lonza does not provide for the entire supply of
the API necessary for our Phase 2 and Phase 3 clinical trials or
for full-scale commercialization. In the event that the parties
cannot agree to the terms and conditions for Lonza to provide
some or all of our API clinical and commercial supply needs, we
would not be able to manufacture API until a qualified
alternative supplier is identified, which could also delay the
development of, and impair our ability to commercialize, this
product candidate.
We currently rely on DSM Pharmaceuticals, Inc. as our single
source supplier for XP19986 formulated in sustained-release
tablets for future clinical trials at specified transfer prices
under quotations agreed upon by the parties as a part of a
master services agreement. In the event that DSM terminates the
agreement under specified
S-15
Table of Contents
circumstances, we would not be able to commercialize XP19986
sustained-release tablets until an alternative supplier is
qualified. This could delay the development of, and impair our
ability to commercialize, XP19986.
We currently rely on Ajinomoto Company as our single source
supplier of L-Dopa, which is used to make XP21279, under
purchase orders issued from time to time. We are aware of
several alternative suppliers of L-Dopa, and we believe at least
one alternative manufacturer could potentially supply L-Dopa, in
the event that Ajinomoto determines to not sell L-Dopa to us at
a price that is commercially attractive. If we were unable to
qualify an alternative supplier of L-Dopa, this could delay the
development of, and impair our ability to commercialize, XP21279.
We have purchased from Raylo Chemicals, Inc., a subsidiary of
Gilead Sciences, Inc., all of our current worldwide requirements
of XP21279 in API form through our Phase 1 clinical trials under
a manufacturing services and product supply agreement. We
recently qualified Piramal Healthcare as an alternative supplier
for manufacture of XP21279 in API form. In the event that the
parties cannot agree to the terms and conditions for Piramal to
provide some or all of our API clinical and commercial supply
needs, we would not be able to manufacture API until a qualified
alternative supplier is identified, which could also delay the
development of, and impair our ability to commercialize, this
product candidate.
We currently rely on Metrics, Inc. as our single source supplier
for XP21279 formulated in sustained-release tablets at specified
transfer prices under quotations agreed upon by the parties as a
part of a master services agreement. In the event that Metrics
terminates the agreement under specified circumstances, we would
not be able to manufacture XP21279 sustained-release tablets
until an alternative supplier is qualified. This could delay the
development of, and impair our ability to commercialize, XP21279.
If we
are required to obtain alternate third-party manufacturers, it
could delay or prevent the clinical development and
commercialization of our product candidates.
We may not be able to maintain or renew our existing or any
other third-party manufacturing arrangements on acceptable
terms, if at all. If we are unable to continue relationships
with Teva, Divis, Hikal or Lonza for XP13512, Excella, Lonza or
DSM for XP19986 or Ajinomoto, Piramal or Metrics for XP21279 or
to continue relationships at an acceptable cost or if these
suppliers fail to meet our requirements for these product
candidates for any reason, we would be required to obtain
alternative suppliers. Any inability to obtain qualified
alternative suppliers, including an inability to obtain, or
delay in obtaining, approval of an alternative supplier from the
FDA, would delay or prevent the clinical development and
commercialization of these product candidates, and could impact
our ability to meet our supply obligations to Astellas.
Use of
third-party manufacturers may increase the risk that we or our
partners will not have adequate supplies of our product
candidates.
Our current reliance, and our and our partners’ anticipated
future reliance, on third-party manufacturers will expose us and
our partners to risks that could delay or prevent the initiation
or completion of clinical trials by us or our partners, the
submission of applications for regulatory approvals, the
approval of our products by the FDA or foreign regulatory
authorities or the commercialization of our products or could
result in higher costs or lost product revenues. In particular,
our contract manufacturers:
| • | could encounter difficulties in achieving volume production, quality control and quality assurance or suffer shortages of qualified personnel, which could result in their inability to manufacture sufficient quantities of drugs to meet clinical schedules or to commercialize our product candidates; | |
| • | could terminate or choose not to renew manufacturing agreements, based on their own business priorities, at a time that is costly or inconvenient for us; | |
| • | could fail to establish and follow FDA-mandated current good manufacturing practices, or cGMPs, which are required for FDA approval of our product candidates, or fail to document their adherence to cGMPs, either of which could lead to significant delays in the availability of material for clinical study and delay or prevent marketing approval for our product candidates; |
S-16
Table of Contents
| • | could encounter financial difficulties that would interfere with their obligations to supply our product candidates; and | |
| • | could breach, or fail to perform as agreed under, manufacturing agreements. |
If we are not able to obtain adequate supplies of our product
candidates, it will be more difficult to develop our product
candidates and compete effectively. Our product candidates and
any products that we may develop may compete with other product
candidates and products for access to manufacturing facilities.
For example, gabapentin is also marketed as generic gabapentin
by Teva, one of our third-party manufacturers.
In addition, the manufacturing facilities of Excella, Lonza,
Teva, Hikal, Divis and Ajinomoto are located outside of the
United States. This may give rise to difficulties in importing
our product candidates or their components into the United
States or other countries as a result of, among other things,
regulatory agency import inspections, incomplete or inaccurate
import documentation or defective packaging.
Safety
issues with the parent drugs or other components of our product
candidates, or with approved products of third parties that are
similar to our product candidates, could give rise to delays in
the regulatory approval process, restrictions on labeling or
product withdrawal.
Discovery of previously unknown problems with an approved
product may result in restrictions on its permissible uses,
including withdrawal of the medicine from the market. The FDA
approved gabapentin, the parent drug for our XP13512 product
candidate, in 1993, and, to date, it has been used in at least
12 million patients. Baclofen, the R-isomer of which is the
parent drug for our XP19986 product candidate, has been used
since 1977. The FDA has not approved the R-isomer of baclofen
for use in humans. The FDA approved levadopa, or L-Dopa, the
parent drug for our XP21279, in 1967. The FDA has not approved
oral tranexamic acid, which is the parent drug for our XP21510
product candidate, although it has been used in European
countries and other countries for many years and is approved in
intravenous form in the United States for tooth extractions in
hemophiliacs. Although gabapentin, baclofen, L-Dopa and
tranexamic acid have been used successfully in patients for many
years, newly observed toxicities, or worsening of known
toxicities, in patients receiving gabapentin, baclofen, L-Dopa
or tranexamic acid could result in increased regulatory scrutiny
of XP13512, XP19986, XP21279 and XP21510, respectively.
Our product candidates are engineered to be broken down by the
body’s natural metabolic processes and to release the
parent drug and other metabolic substances. While these
breakdown products are generally regarded as safe, it is
possible that there could be unexpected toxicity associated with
these breakdown products that will cause any or all of XP13512,
XP19986, XP21279 and XP21510 to be poorly tolerated by, or toxic
to, humans. Any unexpected toxicity of, or suboptimal tolerance
to, our Transported Prodrugs would delay or prevent
commercialization of these product candidates.
Additionally, problems with approved products marketed by third
parties that utilize the same therapeutic target or belong to
the same therapeutic class as the parent drug of our product
candidates could adversely affect the development of our product
candidates. For example, the product withdrawals of Vioxx from
Merck & Co., Inc. and Bextra from Pfizer in 2005 due
to safety issues have caused other drugs that have the same
therapeutic target, such as Celebrex from Pfizer, to receive
additional scrutiny from regulatory authorities. If either
gabapentin or pregabalin, drugs from Pfizer that are marketed as
Neurontin and Lyrica, respectively, encounters unexpected
toxicity problems in humans, the FDA may delay or prevent the
regulatory approval of XP13512 since it is believed to share the
same therapeutic target as gabapentin and pregabalin. In 2005,
the FDA requested that all makers of epilepsy drugs analyze
their clinical trial data to determine whether these drugs
increase the risk of suicide in patients. In December 2008, the
FDA added warnings to 11 antiepileptic drugs, including
gabapentin, regarding an increased risk of suicide or suicidal
thoughts. In April 2009, the FDA approved safety label changes
for all approved antiepileptic drugs, except those indicated
only for short-term use, to include a warning about an increased
risk of suicidal thoughts or actions. At this time, it is
unclear if XP13512, as a compound that is believed to share the
same therapeutic target as gabapentin and pregabalin, would, if
approved by the FDA, require a similar warning in its label.
Finally, if the FDA determines that a drug may present a risk of
substance abuse, it can recommend to the DEA that the drug be
scheduled under the Controlled Substances Act. While gabapentin
is not a scheduled drug at the present time, pregabalin has been
scheduled as a controlled substance. Since pregabalin is a
scheduled drug, it is
S-17
Table of Contents
possible that the FDA may require additional testing of XP13512,
the results of which could lead the FDA to conclude that XP13512
should be scheduled as well. Scheduled substances are subject to
DEA regulations relating to manufacturing, storage, distribution
and physician prescription procedures, and the DEA regulates the
amount of a scheduled substance that is available for clinical
trials and commercial distribution. Accordingly, any scheduling
action that the FDA or DEA may take with respect to XP13512 may
delay its clinical trial and approval process. Any failure or
delay in commencing or completing clinical trials or obtaining
regulatory approvals for our product candidates would delay
commercialization of our product candidates and severely harm
our business and financial condition.
We may
not be successful in our efforts to identify or discover
additional Transported Prodrug candidates.
An important element of our strategy is to identify, develop and
commercialize Transported Prodrugs that improve upon the
absorption, distribution
and/or
metabolism of drugs that have already received regulatory
approval. Research programs to identify new product candidates
require substantial technical, financial and human resources.
These research programs may initially show promise in
identifying potential product candidates, yet fail to yield
product candidates for clinical development for a number of
reasons, including:
| • | the research methodology used may not be successful in identifying potential product candidates; or | |
| • | potential product candidates may, on further study, be shown to have inadequate efficacy, harmful side effects, suboptimal pharmaceutical profile or other characteristics suggesting that they are unlikely to be effective products. |
If we are unable to develop suitable product candidates through
internal research programs or otherwise, we will not be able to
increase our revenues in future periods, which could result in
significant harm to our financial position and adversely impact
our stock price.
Our
product candidates will remain subject to ongoing regulatory
review, even if they receive marketing approval. If we or our
collaborative partners fail to comply with continuing
regulations, these approvals could be rescinded and the sale of
our products could be suspended.
Even if we or our collaborative partners receive regulatory
approval to market a particular product candidate, the approval
could be conditioned on conducting additional, costly,
post-approval studies or could limit the indicated uses included
in the labeling. Moreover, the product may later cause adverse
effects that limit or prevent its widespread use, force us or
our collaborative partners to withdraw it from the market or
impede or delay our or our collaborative partners’ ability
to obtain regulatory approvals in additional countries. In
addition, the manufacturer of the product and its facilities
will continue to be subject to FDA review and periodic
inspections to ensure adherence to applicable regulations. After
receiving marketing approval, the manufacturing, labeling,
packaging, adverse event reporting, storage, advertising,
promotion and record keeping related to the product will remain
subject to extensive regulatory requirements.
If we or our collaborative partners fail to comply with the
regulatory requirements of the FDA and other applicable
U.S. and foreign regulatory authorities or previously
unknown problems with our products, manufacturers or
manufacturing processes are discovered, we and our partners
could be subject to administrative or judicially imposed
sanctions, including:
| • | restrictions on the products, manufacturers or manufacturing processes; | |
| • | warning letters; | |
| • | civil or criminal penalties or fines; | |
| • | injunctions; | |
| • | product seizures, detentions or import bans; | |
| • | voluntary or mandatory product recalls and publicity requirements; |
S-18
Table of Contents
| • | suspension or withdrawal of regulatory approvals; | |
| • | total or partial suspension of production; and | |
| • | refusal to approve pending applications for marketing approval of new drugs or supplements to approved applications. |
Because
we have a number of product candidates and are considering a
variety of target indications, we may expend our limited
resources to pursue a particular candidate or indication and
fail to capitalize on candidates or indications that may be more
profitable or for which there is a greater likelihood of
success.
Because we have limited financial and managerial resources, we
must focus on research programs and product candidates for the
specific indications that we believe are the most promising. As
a result, we may forego or delay pursuit of opportunities with
other product candidates or other indications that later prove
to have greater commercial potential. Our resource allocation
decisions may cause us to fail to capitalize on viable
commercial products or profitable market opportunities. In
addition, we may spend valuable time and managerial and
financial resources on research programs and product candidates
for specific indications that ultimately do not yield any
commercially viable products. If we do not accurately evaluate
the commercial potential or target market for a particular
product candidate, we may relinquish valuable rights to that
product candidate through collaboration, licensing or other
royalty arrangements in situations where it would have been more
advantageous for us to retain sole rights to development and
commercialization.
The
commercial success of any products that we or our partners may
develop will depend upon the degree of market acceptance among
physicians, patients, healthcare payors and the medical
community.
Any products that result from our product candidates may not
gain market acceptance among physicians, patients, healthcare
payors and the medical community. If these products do not
achieve an adequate level of acceptance, we may not generate
material product revenues and we may not become profitable. The
degree of market acceptance of any products resulting from our
product candidates will depend on a number of factors, including:
| • | demonstration of efficacy and safety in clinical trials; | |
| • | the prevalence and severity of any side effects; | |
| • | potential or perceived advantages over alternative treatments; | |
| • | perceptions about the relationship or similarity between our product candidates and the parent drug upon which each Transported Prodrug candidate is based; | |
| • | the timing of market entry relative to competitive treatments; | |
| • | the ability to offer product candidates for sale at competitive prices; | |
| • | relative convenience and ease of administration; | |
| • | the strength of marketing and distribution support; | |
| • | sufficient third-party coverage or reimbursement; and | |
| • | the product labeling or product insert required by the FDA or regulatory authorities in other countries. |
If we
are unable to establish sales and marketing capabilities or
enter into additional agreements with third parties to market
and sell our product candidates, we may be unable to generate
product revenues.
We have a limited sales and marketing organization and have
limited experience in the sales, marketing and distribution of
pharmaceutical products. There are risks involved with
establishing our own sales and marketing capabilities, as well
as entering into arrangements with third parties to perform
these services. Developing an internal sales force is expensive
and time-consuming. On the other hand, if we enter into
arrangements with third
S-19
Table of Contents
parties to perform sales, marketing and distribution services,
as we have for XP13512 around the world, our product revenues
will be lower than if we market and sell any products that we
develop ourselves.
Under the terms of our collaboration with GSK, we are entitled
to a royalty based on a percentage of net sales of XP13512
outside of the United States. In April 2009, we elected the
co-promotion option so that we would share marketing and
commercialization costs and would be entitled to a share of
operating profits from net sales of XP13512 in the United
States. In addition, we would be eligible to receive payments on
details we perform on Requip XL, GSK’s product for
Parkinson’s disease in the United States. Subject to
approval from the FDA of an NDA for XP13512, we would co-promote
XP13512 in the United States to those same prescribers. In
connection with our election of the co-promotion option for
XP13512, we intend to establish our own specialty sales force to
sell and market our products.
Factors that may inhibit our efforts to commercialize our
products include:
| • | our inability to recruit and retain adequate numbers of effective sales and marketing personnel; | |
| • | the inability of sales personnel to obtain access to adequate numbers of physicians to provide information on the advantages and risks of prescribing our products; | |
| • | the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage compared to companies with more extensive product lines; and | |
| • | unforeseen costs and expenses associated with creating an independent sales and marketing organization. |
Because of the numerous risks and uncertainties involved with
establishing our own sales and marketing capabilities, we are
unable to predict when we will establish our own sales and
marketing capabilities. If we are not successful in recruiting
sales and marketing personnel or in building a sales and
marketing infrastructure, we will have difficulty
commercializing our product candidates, which would adversely
affect our business and financial condition.
Our
ability to generate revenue from any products that we may
develop will depend on reimbursement and drug pricing policies
and regulations.
Many patients may be unable to pay for any products that we or
our collaborative partners may develop. In the United States,
many patients will rely on Medicare, Medicaid, private health
insurers and other third-party payors to pay for their medical
needs. Our and our partners’ ability to achieve acceptable
levels of reimbursement for drug treatments by governmental
authorities, private health insurers and other organizations
will have an effect on our and our partners’ ability to
successfully commercialize, and attract additional collaborators
to invest in the development of, our product candidates. We
cannot be sure that reimbursement in the United States, Europe
or elsewhere will be available for any products that we or our
partners may develop, and any reimbursement that may become
available may be decreased or eliminated in the future.
Third-party payors increasingly are challenging prices charged
for medical products and services, and many third-party payors
may refuse to provide reimbursement for particular drugs when an
equivalent generic drug is available. Although we believe any
products that may result from our product candidates will
represent an improvement over the parent drugs upon which they
are based and be considered unique and not subject to
substitution by a generic parent drug, it is possible that a
third-party payor may consider our product candidate and the
generic parent drug as equivalents and only offer to reimburse
patients for the generic drug. Even if we show improved efficacy
or improved convenience of administration with our product
candidate, pricing of the existing parent drug may limit the
amount we will be able to charge for our product candidate. If
reimbursement is not available or is available only at limited
levels, we or our partners may not be able to successfully
commercialize our product candidates, and may not be able to
obtain a satisfactory financial return on such products.
The trend toward managed healthcare in the United States and the
changes in health insurance programs, as well as legislative
proposals to reform healthcare or reduce government insurance
programs, may result in lower prices for pharmaceutical
products, including any products that may result from our
product candidates. In addition, any future regulatory changes
regarding the healthcare industry or third-party coverage and
reimbursement may affect demand for any products that we may
develop and could harm our sales and profitability.
S-20
Table of Contents
Pursuant to the Medicare Prescription Drug Improvement and
Modernization Act of 2003, or the 2003 Medicare Modernization
Act, Medicare beneficiaries are eligible to obtain subsidized
prescription drug coverage from a choice of private sector
plans. Approximately 90 percent of Medicare beneficiaries
now have coverage for prescription medicines. It remains
difficult to predict the long-term impact of the 2003 Medicare
Modernization Act on pharmaceutical companies. The use of
pharmaceuticals has increased slightly among some patients as
the result of the expanded access to medicines afforded by
coverage under Medicare. However, such expanded utilization has
been largely offset by increased pricing pressure and
competition due to the enhanced purchasing power of the private
sector plans that negotiate on behalf of Medicare beneficiaries
and by an increase in the use of generic medicines in this
population. In addition, legislative changes have been proposed
to mandate government rebates in Medicare and to allow the
federal government to directly negotiate prices with
pharmaceutical manufacturers. If legislation were enacted to
mandate rebates or provide for direct government negotiation in
Medicare prescription drug benefits, access and reimbursement
for our product candidates upon commercialization could be
restricted.
If our
competitors are able to develop and market products that are
more effective, safer or less costly than any products that we
may develop, our commercial opportunity will be reduced or
eliminated.
We face competition from established pharmaceutical and
biotechnology companies, as well as from academic institutions,
government agencies and private and public research
institutions. Our commercial opportunity will be reduced or
eliminated if our competitors develop and commercialize products
that are safer, more effective, have fewer side effects or are
less expensive than any products that we may develop. In
addition, significant delays in the development of our product
candidates could allow our competitors to bring products to
market before us and impair our ability to commercialize our
product candidates.
We estimate that we have at least three competitors in the
neuropathic pain, migraine prophylaxis and RLS therapeutic
areas, including Eli Lilly and Company, Johnson &
Johnson and Pfizer. Competition for XP13512 could include:
approved drugs that act on the same target as XP13512, such as
pregabalin, Neurontin and generic gabapentin;
anti-Parkinson’s disease products and product candidates,
such as generic ropinirole from GSK and pramipexole from
Boehringer Ingelheim GmbH, which are each approved for the
treatment of moderate-to-severe primary RLS, and the rotigotine
patch from Schwarz Pharma AG (member of the UCB group), which
filed its NDA for the treatment of moderate-to-severe primary
RLS with the FDA in 2007 and has received a complete response
letter from the FDA; antiepileptics, such as generic topiramate,
which is approved for the prevention of migraines; and serotonin
norepinephrine inhibitors, such as duloxetine from Eli Lilly,
which is approved for the management of painful diabetic
neuropathy. We are aware that generic gabapentin is marketed by
Alpharma Inc., Pfizer, Teva and IVAX Corp, among others. We
estimate that XP19986 could have several generic drug
competitors in the spasticity area. There are several drugs
approved for the treatment of spasticity, such as racemic
baclofen, diazepam, dantrolene sodium and tizanidine, and many
therapies in development, such as Fampridine-SR from Acorda
Therapeutics, Inc. and IPX056 from Impax Laboratories, Inc. that
could compete with XP19986. We estimate that we have at least
five competitors in the GERD therapeutic area, including Wyeth,
Takeda Pharmaceutical Company Limited, Novartis Group, Addex
Pharmaceuticals and AstraZeneca Pharmaceuticals LP. We estimate
that we have at least four competitors in the market for
treating acute back spasms, including Cephalon, Inc., King
Pharmaceuticals, Inc., Johnson & Johnson and Meda
Pharmaceuticals, Inc. Competition for XP21279 could include
generic L-Dopa/carbidopa drugs and other drugs approved for the
treatment of Parkinson’s disease. These include a
combination therapy of L-Dopa/carbidopa/entacapone (marketed in
the United States by Novartis as Stalevo) and dopamine agonists
(marketed by Boehringer-Ingelheim, GSK and UCB as Mirapex,
Requip and Neupro, respectively). We are also aware of an
extended release L-Dopa/carbidopa product candidate that is in
Phase 3 clinical development from Impax. In addition, there may
be other compounds of which we are not aware that are at an
earlier stage of development and may compete with our product
candidates. If any of those compounds are successfully developed
and approved, they could compete directly with our product
candidates.
Many of our competitors have significantly greater financial
resources and expertise in research and development,
manufacturing, preclinical testing, conducting clinical trials,
obtaining regulatory approvals and marketing approved products
than we do. Established pharmaceutical companies may invest
heavily to quickly discover and develop novel compounds that
could make our product candidates obsolete. Smaller or
early-stage companies may also prove to be significant
competitors, particularly through collaborative arrangements
with large
S-21
Table of Contents
and established companies. In addition, these third parties
compete with us in recruiting and retaining qualified scientific
and management personnel, establishing clinical trial sites and
patient registration for clinical trials, as well as in
acquiring technologies and technology licenses complementary to
our programs or advantageous to our business. Accordingly, our
competitors may succeed in obtaining patent protection,
receiving FDA approval or discovering, developing and
commercializing medicines before we do. We are also aware of
other companies that may currently be engaged in the discovery
of medicines that will compete with the product candidates that
we are developing. In addition, in the markets that we are
targeting, we expect to compete against current market-leading
medicines. If we are not able to compete effectively against our
current and future competitors, our business will not grow and
our financial condition will suffer.
Off-label
sale or use of generic gabapentin products could decrease sales
of XP13512 and could lead to pricing pressure if such products
become available at competitive prices and in dosages that are
appropriate for the indications for which we or our
collaborative partners are developing XP13512.
Physicians are permitted to prescribe legally available drugs
for uses that are not described in the drug’s labeling and
that differ from those uses tested and approved by the FDA. Such
off-label uses are common across medical specialties. Various
products are currently sold and used off-label for some of the
diseases and conditions that we or our partners are targeting,
and a number of companies are, or may be, developing new
treatments that may be used off-label. The occurrence of such
off-label uses could significantly reduce our or our
partners’ ability to market and sell any products that we
or our partners may develop.
We believe that in all countries in which we hold or have
licensed rights to patents or patent applications related to
XP13512, the composition-of-matter patents relating to
gabapentin have expired. Off-label prescriptions written for
gabapentin for indications for which we or our partners are
marketing XP13512 could adversely affect our ability to generate
revenue from the sale of XP13512, if approved for commercial
sale. This could result in reduced sales and pricing pressure on
XP13512, if approved, which in turn would reduce our ability to
generate revenue and have a negative impact on our results of
operations.
Our
investment portfolio may become impaired by further
deterioration of the capital markets.
Our cash equivalent and short-term investment portfolio as of
March 31, 2009 consisted of bonds of U.S. government
agencies, corporate debt securities and money market mutual
funds. We follow an established investment policy and set of
guidelines to monitor, manage and limit our exposure to interest
rate and credit risk. The policy sets forth credit quality
standards and limits our exposure to any one issuer, as well as
our maximum exposure to various asset classes.
As a result of current adverse financial market conditions,
investments in some financial instruments, such as structured
investment vehicles, sub-prime mortgage-backed securities and
collateralized debt obligations, may pose risks arising from
liquidity and credit concerns. As of March 31, 2009, we had
no direct holdings in these categories of investments and our
indirect exposure to these financial instruments through our
holdings in money market mutual funds was immaterial. As of
March 31, 2009, we had no impairment charge associated with
our short-term investment portfolio relating to such adverse
financial market conditions. Although we believe our current
investment portfolio has very little risk of impairment, we
cannot predict future market conditions or market liquidity and
can provide no assurance that our investment portfolio will
remain unimpaired.
If we
fail to attract and keep senior management and key scientific
personnel, we may be unable to successfully develop or
commercialize our product candidates.
Our success depends on our continued ability to attract, retain
and motivate highly qualified management, clinical and
scientific personnel and on our ability to develop and maintain
important relationships with leading clinicians. If we are not
able to retain Drs. Ronald Barrett, Kenneth Cundy, Mark
Gallop, David Savello and David Stamler, we may not be able to
successfully develop or commercialize our product candidates.
Competition for experienced scientists and development staff may
limit our ability to hire and retain highly qualified personnel
on acceptable terms. In addition, none of our employees have
employment commitments for any fixed period of time and could
leave our employment at will. We do not carry “key
person” insurance covering members of senior
S-22
Table of Contents
management or key scientific personnel. If we fail to identify,
attract and retain qualified personnel, we may be unable to
continue our development and commercialization activities.
We
will need to hire additional employees in order to commercialize
our product candidates. Any inability to manage future growth
could harm our ability to commercialize our product candidates,
increase our costs and adversely impact our ability to compete
effectively.
In order to commercialize our product candidates, we will need
to expand the number of our managerial, operational, financial
and other employees. We currently anticipate that we will need
at least 65 additional employees by the time that XP13512 or
XP19986 is initially commercialized, including at least 50 sales
representatives. Because the projected timeframe of hiring these
additional employees depends on the development status of our
product candidates and because of the numerous risks and
uncertainties associated with drug development, we are unable to
project when we will hire these additional employees. The
competition for qualified personnel in the pharmaceutical and
biotechnology field is intense, and we may experience
difficulties in recruiting, hiring and retaining qualified
individuals.
Future growth will impose significant added responsibilities on
members of management, including the need to identify, recruit,
maintain and integrate additional employees. Our future
financial performance and our ability to commercialize our
product candidates and compete effectively will depend, in part,
on our ability to manage any future growth effectively.
If
product liability lawsuits are brought against us, we will incur
substantial liabilities and may be required to limit
commercialization of any products that we may
develop.
We face an inherent risk of product liability exposure related
to the testing of our product candidates in human clinical
trials and will face an even greater risk if we commercially
sell any products that we may develop. If we cannot successfully
defend ourselves against claims that our product candidates or
products that we may develop caused injuries, we will incur
substantial liabilities.
Regardless of merit or eventual outcome, liability claims may
result in:
| • | decreased demand for any product candidates or products that we may develop; | |
| • | injury to our reputation; | |
| • | withdrawal of clinical trial participants; | |
| • | costs to defend the related litigation; | |
| • | substantial monetary awards to clinical trial participants or patients; | |
| • | loss of revenue; and | |
| • | the inability to commercialize any products that we may develop. |
We have product liability insurance that covers our clinical
trials up to a $10.0 million annual aggregate limit. We
intend to expand our insurance coverage to include the sale of
commercial products if marketing approval is obtained for any
products that we may develop. Insurance coverage is increasingly
expensive, and we may not be able to maintain insurance coverage
at a reasonable cost and we may not be able to obtain insurance
coverage that will be adequate to satisfy any liability that may
arise.
If we
use biological and hazardous materials in a manner that causes
contamination or injury or violates laws, we may be liable for
damages.
Our research and development activities involve the use of
potentially harmful biological materials as well as hazardous
materials, chemicals and various radioactive compounds. We
cannot completely eliminate the risk of accidental contamination
or injury from the use, storage, handling or disposal of these
materials. In the event of contamination or injury, we could be
held liable for damages that result, and any liability could
exceed our resources. We, the third parties that conduct
clinical trials on our behalf and the third parties that
manufacture our
S-23
Table of Contents
product candidates are subject to federal, state and local laws
and regulations governing the use, storage, handling and
disposal of these materials and waste products. The cost of
compliance with these laws and regulations could be significant.
The failure to comply with these laws and regulations could
result in significant fines and work stoppages and may harm our
business.
Our facility is located in California’s Silicon Valley, in
an area with a long history of industrial activity and use of
hazardous substances, including chlorinated solvents.
Environmental studies conducted prior to our leasing of the site
found levels of metals and volatile organic compounds in the
soils and groundwater at our site. While these constituents of
concern predated our occupancy, certain environmental laws,
including the U.S. Comprehensive, Environmental Response,
Compensation and Liability Act of 1980, impose strict, joint and
several liability on current operators of real property for the
cost of removal or remediation of hazardous substances. These
laws often impose liability even if the owner or operator did
not know of, or was not responsible for, the release of such
hazardous substances. As a result, while we have not been, we
cannot rule out the possibility that we could in the future be
held liable for costs to address contamination at the property
beneath our facility, which costs could be material.
Our
facility is located near known earthquake fault zones, and the
occurrence of an earthquake, extremist attack or other
catastrophic disaster could cause damage to our facilities and
equipment, which could require us to cease or curtail
operations.
Our facility is located near known earthquake fault zones and,
therefore, is vulnerable to damage from earthquakes. In October
1989, a major earthquake struck this area and caused significant
property damage and a number of fatalities. We are also
vulnerable to damage from other types of disasters, including
power loss, attacks from extremist organizations, fire, floods
and similar events. If any disaster were to occur, our ability
to operate our business could be seriously impaired. In
addition, the unique nature of our research activities and of
much of our equipment could make it difficult for us to recover
from this type of disaster. We currently may not have adequate
insurance to cover our losses resulting from disasters or other
similar significant business interruptions, and we do not plan
to purchase additional insurance to cover such losses due to the
cost of obtaining such coverage. Any significant losses that are
not recoverable under our insurance policies could seriously
impair our business and financial condition.
Risks
Related to this Offering and Ownership of our Common
Stock
Our
stock price is volatile, and purchasers of our common stock
could incur substantial losses.
The market prices for securities of biopharmaceutical companies
in general have been highly volatile. The market price of our
common stock may be influenced by many factors, including:
| • | adverse results or delays in our or our collaborative partners’ clinical trials; | |
| • | the timing of achievement of our clinical, regulatory, partnering and other milestones, such as the commencement of clinical development, the completion of a clinical trial, the filing for regulatory approval or the establishment of commercial partnerships for one or more of our product candidates; | |
| • | announcement of FDA approvability, approval or non-approval of our product candidates or delays in the FDA review process; | |
| • | actions taken by regulatory agencies with respect to our product candidates, our clinical trials or our sales and marketing activities; | |
| • | actions taken by regulatory agencies with respect to products or drug classes related to our product candidates; | |
| • | the commercial success of any of our products approved by the FDA or its foreign counterparts; | |
| • | changes in our collaborators’ business strategies; | |
| • | regulatory developments in the United States and foreign countries; |
S-24
Table of Contents
| • | changes in the structure of healthcare payment systems; | |
| • | any intellectual property matter involving us, including infringement lawsuits; | |
| • | actions taken by regulatory agencies with respect to our or our partners’ compliance with regulatory requirements; | |
| • | announcements of technological innovations or new products by us or our competitors; | |
| • | market conditions for equity investments in general, or the biotechnology or pharmaceutical industries in particular; | |
| • | changes in financial estimates or recommendations by securities analysts; | |
| • | sales of large blocks of our common stock; | |
| • | sales of our common stock by our executive officers, directors and significant stockholders; | |
| • | restatements of our financial results and/or material weaknesses in our internal controls; and | |
| • | the loss of any of our key scientific or management personnel. |
The stock markets in general, and the markets for biotechnology
stocks in particular, have experienced extreme volatility that
has often been unrelated to the operating performance of
particular companies. These broad market fluctuations may
adversely affect the trading price of our common stock. In the
past, class action litigation has often been instituted against
companies whose securities have experienced periods of
volatility in market price. Any such litigation brought against
us could result in substantial costs, which would hurt our
financial condition and results of operations, divert
management’s attention and resources and possibly delay our
clinical trials or commercialization efforts.
Failure
to maintain effective internal controls in accordance with
Section 404 of the Sarbanes-Oxley Act of 2002 could have a
material adverse effect on our stock price.
Section 404 of the Sarbanes-Oxley Act of 2002 and the
related rules and regulations of the SEC require annual
management assessments of the effectiveness of our internal
control over financial reporting and a report by our independent
registered public accounting firm attesting to, and reporting
on, the effectiveness of our internal control over financial
reporting. If we fail to maintain the adequacy of our internal
control over financial reporting, as such standards are
modified, supplemented or amended from time to time, we may not
be able to ensure that we can conclude on an ongoing basis that
we have effective internal control over financial reporting in
accordance with Section 404 of the Sarbanes-Oxley Act of
2002 and the related rules and regulations of the SEC. If we
cannot favorably assess, or our independent registered public
accounting firm is unable to provide an unqualified attestation
report on, the effectiveness of our internal control over
financial reporting, investor confidence in the reliability of
our financial reports may be adversely affected, which could
have a material adverse effect on our stock price.
Fluctuations
in our operating results could cause our stock price to
decline.
The following factors are likely to result in fluctuations of
our operating results from quarter to quarter and year to year:
| • | adverse results or delays in our or our collaborative partners’ clinical trials; | |
| • | the timing and achievement of our clinical, regulatory, partnering and other milestones, such as the commencement of clinical development, the completion of a clinical trial, the filing for regulatory approval or the establishment of a commercial partnership for one or more of our product candidates; | |
| • | announcement of FDA approvability, approval or non-approval of our product candidates or delays in the FDA review process; | |
| • | actions taken by regulatory agencies with respect to our product candidates, our clinical trials or our sales and marketing activities; |
S-25
Table of Contents
| • | actions taken by regulatory agencies with respect to products or drug classes related to our product candidates; | |
| • | the commercial success of any of our products approved by the FDA or its foreign counterparts; | |
| • | changes in our collaborators’ business strategies; | |
| • | actions taken by regulatory agencies with respect to our or our partners’ compliance with regulatory requirements; | |
| • | regulatory developments in the United States and foreign countries; | |
| • | changes in the structure of healthcare payment systems; | |
| • | any intellectual property matter involving us, including infringement lawsuits; and | |
| • | announcements of technological innovations or new products by us or our competitors. |
Due to these fluctuations in our operating results, a
period-to-period comparison of our results of operations may not
be a good predictor of our future performance. For example, due
to the recognition of revenues from up-front and milestone
payments from our collaborations with Astellas, GSK and
Xanodyne, we were profitable in the three-month periods ended
June 30, September 30 and December 31, 2007, and for
the year ended December 31, 2007. However, while
recognition of these revenues resulted in a profitable year for
2007, we incurred net losses in 2008, and we continue to expect
to incur net losses in 2009. In any particular financial period,
the actual or anticipated fluctuations could be below the
expectations of securities analysts or investors and our stock
price could decline.
Because
a small number of existing stockholders own a large percentage
of our voting stock, they may be able to exercise significant
influence over our affairs, acting in their best interests and
not necessarily those of other stockholders.
As of April 15, 2009, our executive officers, directors and
holders of 5% or more of our outstanding common stock
beneficially owned approximately 52.7% of our common stock. The
interests of this group of stockholders may not always coincide
with our interests or the interests of other stockholders. This
concentration of ownership could also have the effect of
delaying or preventing a change in our control or otherwise
discouraging a potential acquiror from attempting to obtain
control of us, which in turn could reduce the price of our
common stock.
Our
stockholder rights plan and anti-takeover provisions in our
charter documents and under Delaware law could make an
acquisition of us, which may be beneficial to our stockholders,
more difficult and may prevent attempts by our stockholders to
replace or remove our current management.
Provisions in our amended and restated certificate of
incorporation and bylaws may delay or prevent an acquisition of
us, a change in our management or other changes that
stockholders may consider favorable. These provisions include:
| • | a classified board of directors; | |
| • | a prohibition on actions by our stockholders by written consent; | |
| • | the ability of our board of directors to issue preferred stock without stockholder approval, which could be used to make it difficult for a third party to acquire us; | |
| • | notice requirements for nominations for election to the board of directors; and | |
| • | limitations on the removal of directors. |
Moreover, we are governed by the provisions of Section 203
of the Delaware General Corporation Law, which prohibits a
person who owns in excess of 15% of our outstanding voting stock
from merging or combining with us for a period of three years
after the date of the transaction in which the person acquired
in excess of 15% of our outstanding voting stock, unless the
merger or combination is approved in a prescribed manner.
S-26
Table of Contents
We have adopted a rights agreement under which certain
stockholders have the right to purchase shares of a new series
of preferred stock at an exercise price of $140.00 per one
one-hundredth of a share, if a person acquires more than 15% of
our common stock. The rights plan could make it more difficult
for a person to acquire a majority of our outstanding voting
stock. The rights plan could also reduce the price that
investors might be willing to pay for shares of our common stock
and result in the market price being lower than it would be
without the rights plan. In addition, the existence of the
rights plan itself may deter a potential acquiror from acquiring
us. As a result, either by operation of the rights plan or by
its potential deterrent effect, mergers and acquisitions of us
that our stockholders may consider in their best interests may
not occur.
If
there are large sales of our common stock, the market price of
our common stock could drop substantially.
If our existing stockholders sell a large number of shares of
our common stock or the public market perceives that existing
stockholders might sell shares of our common stock, the market
price of our common stock could decline significantly. As of
April 15, 2009, we had 27,311,219 outstanding shares of
common stock. Of these shares, up to 14,692,760 shares of
common stock are tradable under Rule 144 under the
Securities Act of 1933, as amended, or the Securities Act,
subject in some cases to the volume limitations and manner of
sale requirements under Rule 144, and the remainder of the
shares outstanding as of April 15, 2009, have been
registered under the Securities Act and are freely tradable. In
addition, all of the shares offered pursuant this prospectus
supplement and the accompanying prospectus will be freely
tradable without restriction or further registration unless
purchased by our affiliates.
Our executive officers and directors have agreed that, subject
to certain limited exceptions, during the period ending
90 days after the date of this prospectus supplement, they
will not sell, pledge or otherwise dispose of shares of our
common stock or any securities convertible into or exchangeable
for our common stock, without the prior written consent of
Morgan Stanley & Co. Incorporated and Goldman,
Sachs & Co., who may release any of the securities
subject to these
lock-up
agreements at any time without notice.
We
have broad discretion in the use of the net proceeds from this
offering and may not use them effectively.
We will have broad discretion in the application of the net
proceeds from this offering and could spend the proceeds in ways
that do not improve our results of operations or enhance the
value of our common stock. Our failure to apply these funds
effectively could have a material adverse effect on our
business, delay the development of our product candidates and
cause the price of our common stock to decline.
S-27
Table of Contents
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus supplement, the accompanying prospectus, the
documents we have filed with the SEC that are incorporated
herein by reference and any free writing prospectus that we have
authorized for use in connection with this offering contain
forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as
amended. These statements are based on our current expectations,
assumptions, estimates and projections about our business and
our industry, and involve known and unknown risks, uncertainties
and other factors that may cause our results, levels of
activity, performance or achievement to be materially different
from any future results, levels of activity, performance or
achievements expressed or implied by the forward-looking
statements. Forward-looking statements include, but are not
limited to, statements about:
| • | our ability to obtain and maintain regulatory approvals for our product candidates; | |
| • | our expectations with respect to potential commercialization of any of our product candidates; | |
| • | the success and timing of our preclinical studies and clinical trials; | |
| • | our plans to research, develop and commercialize our product candidates; | |
| • | the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing, and our ability to obtain additional financing; and | |
| • | our ability to obtain and maintain intellectual property protection for our product candidates. |
In some cases, you can identify forward-looking statements by
terms such as “anticipate,” “believe,”
“could,” “estimate,” “expect,”
“intend,” “may,” “plan,”
“potential,” “predict,” “project,”
“should,” “will,” “would” and
similar expressions intended to identify forward-looking
statements. While we believe that we have a reasonable basis for
each forward-looking statement, we caution you that these
statements are based on a combination of facts and factors
currently known by us and our projections of the future, about
which we cannot be certain. We discuss many of these risks,
uncertainties and other factors in greater detail under the
heading “Risk Factors” contained in this prospectus
supplement. Given these risks, uncertainties and other factors,
you should not place undue reliance on these forward-looking
statements. Also, these forward-looking statements represent our
estimates and assumptions only as of the date such
forward-looking statements are made. You should read carefully
both this prospectus supplement and the accompanying prospectus,
together with the information incorporated herein by reference
as described under the heading “Where You Can Find More
Information” in this prospectus supplement, completely and
with the understanding that our actual future results may be
materially different from what we expect. We hereby qualify all
of our forward-looking statements by these cautionary statements.
Except as required by law, we assume no obligation to update
these forward-looking statements publicly, or to update the
reasons actual results could differ materially from those
anticipated in these forward-looking statements, even if new
information becomes available in the future.
S-28
Table of Contents
USE OF
PROCEEDS
We estimate that the net proceeds from the sale of the
2,500,000 shares of common stock that we are offering will
be approximately $44.4 million, or approximately
$51.1 million if the underwriters exercise in full their
option to purchase 375,000 additional shares of common stock,
based on the public offering price of $19.00 per share and after
deducting the underwriting discounts and commissions and
estimated offering expenses payable by us.
We currently expect to use the net proceeds from this offering
for general corporate purposes, including clinical trial,
research and development, general and administrative and
manufacturing expenses, as well as for potential sales and
marketing activities. We may also use a portion of the proceeds
for the potential acquisition of, or investment in,
technologies, products or companies that complement our
business, although we have no current understandings,
commitments or agreements to do so.
The amounts and timing of our actual expenditures will depend
upon numerous factors, including the status of our development
and commercialization efforts, the timing of regulatory
approvals, if any, the amount of proceeds actually raised in
this offering, the amount of cash generated through our existing
strategic collaborations and any additional strategic
collaborations into which we may enter. Accordingly, our
management will have significant flexibility in applying the net
proceeds of this offering.
Until the funds are used as described above, we intend to invest
the net proceeds from this offering in interest-bearing,
investment grade securities.
S-29
Table of Contents
CAPITALIZATION
The following table sets forth our cash, cash equivalents and
short-term investments and our capitalization as of
March 31, 2009:
| • | on an actual basis; and | |
| • | on an as adjusted basis to give effect to the sale by us of 2,500,000 shares of our common stock in this offering at the public offering price of $19.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. |
You should read this information in conjunction with our
financial statements and other financial information that are
included, or incorporated by reference, in this prospectus
supplement and the accompanying prospectus.
| As of March 31, 2009 | ||||||||
| Actual | As Adjusted | |||||||
|
(Unaudited) |
||||||||
| (In thousands, except for share and per share data) | ||||||||
|
Cash, cash equivalents and short-term investments
|
$ | 143,332 | $ | 187,689 | ||||
|
Restricted investments
|
1,835 | 1,835 | ||||||
|
Total
|
$ | 145,167 | $ | 189,524 | ||||
|
Stockholders’ equity:
|
||||||||
|
Common stock: $0.001 par value; 60,000,000 shares
authorized; 27,310,755 shares issued and outstanding
actual; 29,810,755 shares issued and outstanding as adjusted
|
27 | 30 | ||||||
|
Additional paid-in capital
|
365,063 | 409,417 | ||||||
|
Accumulated other comprehensive income
|
231 | 231 | ||||||
|
Accumulated deficit
|
(241,301 | ) | (241,301 | ) | ||||
|
Total stockholders’ equity
|
124,020 | 168,377 | ||||||
|
Total capitalization
|
$ | 124,020 | $ | 168,377 | ||||
The number of shares shown as issued and outstanding in the
table above excludes, as of March 31, 2009:
| • | 3,832,952 shares of our common stock issuable upon the exercise of outstanding options, having a weighted-average exercise price of $27.73 per share; | |
| • | 290,099 shares of our common stock issuable upon the vesting of outstanding restricted stock unit awards; | |
| • | 304,752 shares of our common stock issuable upon the exercise of outstanding warrants, having a weighted-average exercise price of $24.95 per share; and | |
| • | an aggregate of 2,045,222 shares of our common stock reserved for future issuance under our 2005 Equity Incentive Plan, our 2005 Non-Employee Directors’ Stock Option Plan and our 2005 Employee Stock Purchase Plan. |
S-30
Table of Contents
DILUTION
Our net tangible book value as of March 31, 2009 was
approximately $124.0 million, or $4.54 per share. Net
tangible book value per share is determined by dividing our
total tangible assets, less total liabilities, by the number of
shares of our common stock outstanding as of March 31,
2009. Dilution in net tangible book value per share represents
the difference between the amount per share paid by purchasers
of shares of common stock in this offering and the net tangible
book value per share of our common stock immediately after this
offering.
After giving effect to our sale of 2,500,000 shares of our
common stock in this offering at the public offering price of
$19.00 per share and after deducting the underwriting discounts
and commissions and estimated offering expenses payable by us,
our as adjusted net tangible book value as of March 31,
2009 would have been approximately $168.4 million, or $5.65
per share. This represents an immediate increase in net tangible
book value of $1.11 per share to existing stockholders and
immediate dilution in net tangible book value of $13.35 per
share to new investors purchasing our common stock in this
offering at the public offering price. The following table
illustrates this dilution on a per share basis:
|
Public offering price per share
|
$ | 19.00 | ||||||
|
Net tangible book value per share as of March 31, 2009
|
$ | 4.54 | ||||||
|
Increase per share attributable to new investors
|
1.11 | |||||||
|
As adjusted net tangible book value per share after this offering
|
5.65 | |||||||
|
Dilution per share to new investors
|
$ | 13.35 | ||||||
If the underwriters exercise in full their option to purchase
375,000 additional shares of common stock, the as adjusted net
tangible book value after this offering would be $5.80 per
share, representing an increase in net tangible book value of
$1.26 per share to existing stockholders and immediate dilution
in net tangible book value of $13.20 per share to new investors
purchasing our common stock in this offering at the public
offering price.
The above discussion and table are based on
27,310,755 shares of common stock issued and outstanding as
of March 31, 2009 and exclude:
| • | 3,832,952 shares of our common stock issuable upon the exercise of options outstanding as of March 31, 2009, having a weighted-average exercise price of $27.73 per share; | |
| • | 290,099 shares of our common stock issuable upon the vesting of restricted stock unit awards outstanding as of March 31, 2009; | |
| • | 304,752 shares of our common stock issuable upon the exercise of warrants outstanding as of March 31, 2009, having a weighted-average exercise price of $24.95 per share; and | |
| • | an aggregate of 2,045,222 shares of our common stock reserved for future issuance as of March 31, 2009 under our 2005 Equity Incentive Plan, our 2005 Non-Employee Directors’ Stock Option Plan and our 2005 Employee Stock Purchase Plan. |
To the extent that outstanding options or warrants are exercised
or restricted stock unit awards vest, you will experience
further dilution. In addition, we may choose to raise additional
capital due to market conditions or strategic considerations
even if we believe that we have sufficient funds for our current
or future operating plans. To the extent that additional capital
is raised through the sale of equity or convertible debt
securities, the issuance of these securities could result in
further dilution to our stockholders.
S-31
Table of Contents
MATERIAL
U.S. FEDERAL INCOME TAX CONSEQUENCES
TO NON-U.S. HOLDERS
TO NON-U.S. HOLDERS
The following summary describes the material U.S. federal
income and estate tax consequences of the acquisition, ownership
and disposition of common stock acquired in this offering by a
Non-U.S. Holder
(as defined below). This discussion does not address all aspects
of U.S. federal income and estate taxes and does not deal
with foreign, state and local consequences that may be relevant
to
Non-U.S. Holders
in light of their particular circumstances. Special rules may
apply to certain
Non-U.S. Holders
that are subject to special treatment under the Internal Revenue
Code of 1986, as amended, or the Code, such as financial
institutions, insurance companies, tax-exempt organizations,
broker-dealers and traders in securities, U.S. expatriates,
“controlled foreign corporations,” “passive
foreign investment companies,” corporations that accumulate
earnings to avoid U.S. federal income tax, persons that
hold our common stock as part of a “straddle,”
“hedge,” “conversion transaction,”
“synthetic security” or integrated investment,
partnerships and other pass-through entities, and investors in
such pass-through entities. Such
Non-U.S. Holders
are urged to consult their own tax advisors to determine the
U.S. federal, state, local and other tax consequences that
may be relevant to them. Furthermore, the discussion below is
based upon the provisions of the Code, and Treasury regulations,
rulings and judicial decisions thereunder as of the date hereof,
and such authorities may be repealed, revoked or modified,
perhaps retroactively, so as to result in U.S. federal
income and estate tax consequences different from those
discussed below. This discussion assumes that the
Non-U.S. Holder
holds our common stock as a capital asset.
The following discussion is for general information only and is
not tax advice. Persons considering the purchase of common stock
should consult their own tax advisors concerning the
U.S. federal income and estate tax consequences in light of
their particular situations as well as any consequences arising
under the laws of any other taxing jurisdiction, including any
state, local or foreign tax consequences.
Except as otherwise described in the discussion of estate tax
below, a
“Non-U.S. Holder”
is a beneficial holder of common stock that is not a
U.S. Holder. A “U.S. Holder” means a
beneficial holder of common stock that is for U.S. federal
income tax purposes (i) an individual who is a citizen or
resident of the United States, (ii) a corporation or other
entity treated as a corporation created or organized in or under
the laws of the United States or any political subdivision
thereof, (iii) an estate the income of which is subject to
U.S. federal income taxation regardless of its source or
(iv) a trust if it (x) is subject to the primary
supervision of a court within the United States and one or more
U.S. persons have the authority to control all substantial
decisions of the trust or (y) has a valid election in
effect under applicable U.S. Treasury regulations to be
treated as a U.S. person.
If a partnership (including any entity or arrangement treated as
a partnership for U.S. federal income tax purposes)
acquires common stock, the tax treatment of a partner in the
partnership will generally depend upon the status of the partner
and the activities of the partnership. Persons who are partners
of partnerships holding the common stock are urged to consult
their tax advisors.
Distributions
Subject to the discussion below, distributions, if any, made to
a
Non-U.S. Holder
of our common stock out of our current or accumulated earnings
and profits generally will constitute dividends for
U.S. tax purposes and will be subject to withholding tax at
a 30% rate or such lower rate as may be specified by an
applicable income tax treaty. To obtain a reduced rate of
withholding under a treaty, a
Non-U.S. Holder
generally will be required to provide us with a
properly-executed IRS
Form W-8BEN,
or other appropriate form, certifying the
Non-U.S. Holder’s
entitlement to benefits under that treaty. Treasury Regulations
provide special rules to determine whether, for purposes of
determining the applicability of a tax treaty, dividends paid to
a
Non-U.S. Holder
that is an entity should be treated as paid to the entity or to
those holding an interest in that entity. If a
Non-U.S. Holder
holds stock through a financial institution or other agent
acting on the holder’s behalf, the holder will be required
to provide appropriate documentation to such agent. The
holder’s agent will then be required to provide
certification to us or our paying agent, either directly or
through other intermediaries.
We generally are not required to withhold tax on dividends paid
to a
Non-U.S. Holder
that are effectively connected with the
Non-U.S. Holder’s
conduct of a trade or business within the United States if a
properly-executed IRS FormW-8ECI, stating that the dividends are
so connected, is filed with us. Effectively connected dividends
will
S-32
Table of Contents
be subject to U.S. federal income tax, generally in the
same manner and at the regular rate as if the
Non-U.S. Holder
were a U.S. citizen or resident alien or a domestic
corporation, as the case may be, unless a specific treaty
exemption applies. If the
Non-U.S. Holder
is eligible for the benefits of a tax treaty between the United
States and the holder’s country of residence, any
effectively connected dividends would generally be subject to
U.S. federal income tax only if they are also attributable
to a permanent establishment maintained by the holder in the
United States. A corporate
Non-U.S. Holder
receiving effectively connected dividends may also be subject to
an additional “branch profits tax”, which is imposed,
under certain circumstances, at a rate of 30% (or such lower
rate as may be specified by an applicable treaty) of the
corporate
Non-U.S. Holder’s
effectively connected earnings and profits, subject to certain
adjustments. If you are eligible for a reduced rate of
withholding tax pursuant to a tax treaty, you may generally
obtain a refund of any excess amounts currently withheld if you
file an appropriate claim for refund with the IRS.
To the extent distributions on our common stock, if any, exceed
our current and accumulated earnings and profits, they will
constitute a return of capital and will first reduce your basis
in our common stock, but not below zero, and then will be
treated as gain from the sale of stock.
Gain on
disposition of common stock
A
Non-U.S. Holder
generally will not be subject to U.S. federal income tax
with respect to gain realized on a sale or other disposition of
our common stock unless (i) the gain is effectively
connected with a trade or business of such holder in the United
States, (ii) in the case of
Non-U.S. Holders
who are nonresident alien individuals, such individuals are
present in the United States for 183 or more days in the taxable
year of the disposition and certain other conditions are met, or
(iii) we are or have been a “United States real
property holding corporation” within the meaning of Code
Section 897(c)(2) at any time within the shorter of the
five-year period preceding such disposition or such
holder’s holding period. In general, we would be a United
States real property holding corporation if interests in
U.S. real estate comprised at least half of our business
assets. We believe that we are not, and do not anticipate
becoming, a United States real property holding corporation.
Even if we are treated as a United States real property holding
corporation, gain realized by a
Non-U.S. Holder
on a disposition of our common stock will not be subject to
U.S. federal income tax so long as (1) the
Non-U.S. Holder
owned directly, indirectly and constructively, no more than five
percent of our common stock at all times within the shorter of
(a) the five year period preceding the disposition or
(b) the holder’s holding period and (2) our
common stock is regularly traded on an established securities
market. There can be no assurance that our common stock will
continue to qualify as regularly traded on an established
securities market.
If you are a
Non-U.S. Holder
described in (i) above, you will be required to pay tax on
the net gain derived from the sale at generally applicable
United States federal income tax rates, subject to an applicable
income tax treaty providing otherwise, and corporate
Non-U.S. Holders
described in (i) above may be subject to the branch profits
tax at a 30% rate or such lower rate as may be specified by an
applicable income tax treaty. If you are an individual
Non-U.S. Holder
described in (ii) above, you will be required to pay a flat
30% tax (or a reduced rate under an applicable income tax
treaty) on the gain derived from the sale, which tax may be
offset by U.S. source capital losses if you have timely
filed tax returns with respect to such losses (even though you
are not considered a resident of the United States).
Information
reporting and backup withholding
Generally, we must report to the IRS the amount of dividends
paid, the name and address of the recipient, and the amount, if
any, of tax withheld. A similar report is sent to the holder.
Pursuant to tax treaties or certain other agreements, the IRS
may make its reports available to tax authorities in the
recipient’s country of residence. Backup withholding will
generally not apply to payments of dividends made by us or our
paying agents to a
Non-U.S. Holder
if the holder has provided its federal taxpayer identification
number, if any, or the required certification that it is not a
U.S. person (which is generally provided by furnishing a
properly-executed IRS
Form W-8BEN),
unless the payer otherwise has knowledge or reason to know that
the payee is a U.S. person. The backup withholding rate is
currently 28 percent. Backup withholding is generally not
required on payments to corporations, whether domestic or
foreign.
S-33
Table of Contents
Under current U.S. federal income tax law, information
reporting and backup withholding will apply to the proceeds of a
disposition of our common stock effected by or through a
U.S. office of a broker unless the disposing holder
certifies as to its
non-U.S. status
or otherwise establishes an exemption. The certification
procedures for claiming benefits under a tax treaty described in
“— Distributions” above will satisfy the
certification requirements to avoid backup withholding as well.
Generally, U.S. information reporting and backup
withholding will not apply to a payment of disposition proceeds
where the transaction is effected outside the United States
through a
non-U.S. office
of a
non-U.S. broker.
Backup withholding will apply to a payment of disposition
proceeds if the broker has actual knowledge or reason to know
that the holder is a U.S. person.
Backup withholding is not an additional tax. Rather, the tax
liability of persons subject to backup withholding will be
reduced by the amount of tax withheld. If withholding results in
an overpayment of taxes, a refund may generally be obtained,
provided that the required information is timely furnished to
the IRS.
Federal
estate tax
An individual who at the time of death is not a citizen or
resident of the United States and who is treated as the owner
of, or has made certain lifetime transfers of, an interest in
our common stock will be required to include the value thereof
in his or her taxable estate for U.S. federal estate tax
purposes, and may be subject to U.S. federal estate tax
unless an applicable estate tax treaty provides otherwise. The
test for whether an individual is a resident of the United
States for federal estate tax purposes differs from the test
used for U.S. federal income tax purposes. Some
individuals, therefore, may be
“Non-U.S. Holders”
for U.S. federal income tax purposes, but not for
U.S. federal estate tax purposes, and vice versa.
THE PRECEDING DISCUSSION OF U.S. FEDERAL INCOME TAX
CONSIDERATIONS IS FOR GENERAL INFORMATION ONLY. IT IS NOT TAX
ADVICE. EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX
ADVISOR REGARDING THE TAX CONSEQUENCES OF PURCHASING, HOLDING
AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF
ANY PROPOSED CHANGE IN APPLICABLE LAW.
S-34
Table of Contents
UNDERWRITERS
Under the terms and subject to the conditions contained in an
underwriting agreement dated the date of this prospectus
supplement, the underwriters named below have severally agreed
to purchase and we have agreed to sell to them, severally, the
number of shares indicated below:
|
Name
|
Number of Shares | |||
|
Morgan Stanley & Co. Incorporated
|
1,375,000 | |||
|
Goldman, Sachs & Co.
|
1,125,000 | |||
|
Total
|
2,500,000 | |||
The underwriters are offering the shares of common stock subject
to their acceptance of the shares from us and subject to prior
sale. The underwriting agreement provides that the obligations
of the several underwriters to pay for and accept delivery of
the shares of common stock offered by this prospectus supplement
are subject to the approval of certain legal matters by their
counsel and to certain other conditions. The underwriters are
obligated to take and pay for all of the shares of common stock
offered by this prospectus supplement if any such shares are
taken. However, the underwriters are not required to take or pay
for the shares covered by the underwriters’ over-allotment
option described below.
The underwriters initially propose to offer part of the shares
of common stock directly to the public at the public offering
price listed on the cover page of this prospectus supplement and
part to certain dealers at a price that represents a concession
not in excess of $0.65 a share under the public offering price.
After the initial offering of the shares of common stock, the
offering price and other selling terms may from time to time be
varied by the underwriters.
We have granted to the underwriters an option, exercisable for
30 days from the date of this prospectus supplement, to
purchase up to an aggregate of 375,000 additional shares of
common stock at the public offering price set forth on the cover
page of this prospectus supplement, less underwriting discounts
and commissions. The underwriters may exercise this option
solely for the purpose of covering over-allotments, if any, made
in connection with the offering of the shares of common stock
offered by this prospectus supplement. To the extent the option
is exercised, each underwriter will become obligated, subject to
certain conditions, to purchase about the same percentage of the
additional shares of common stock as the number listed next to
the underwriter’s name in the preceding table bears to the
total number of shares of common stock listed next to the names
of all underwriters in the preceding table. If the
underwriters’ over-allotment option is exercised in full,
the total price to the public would be $54,625,000, the total
underwriters’ discounts and commissions would be
$3,140,938, and the gross proceeds to us, taking into account
such underwriters’ discounts and commissions, would be
$51,484,062.
The underwriters have informed us that they do not intend sales
to discretionary accounts to exceed five percent of the total
number of shares of common stock offered by them.
We and each of our directors and executive officers have agreed
that, among other things, without the prior written consent of
Morgan Stanley & Co. Incorporated and Goldman,
Sachs & Co., we and they will not, during the period
ending 90 days after the date of this prospectus supplement:
| • | offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for common stock; or | |
| • | enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock; |
S-35
Table of Contents
whether any such transaction described above is to be settled by
delivery of common stock or such other securities, in cash or
otherwise. The restrictions described in this paragraph do not
apply to:
| • | the sale of shares by us to the underwriters; | |
| • | the sale, issuance or transfer by us of shares of common stock in connection with equity compensation arrangements, the grant of equity compensation awards by us, or the issuance of common stock by us upon the exercise of outstanding warrants; | |
| • | transactions by any person other than us relating to shares of common stock or other securities acquired in open market transactions after the completion of the offering of the shares; | |
| • | the sale of common stock pursuant to an existing 10b5-1 plan which is disclosed to the underwriters prior to the offering of the shares; | |
| • | the entry into a 10b5-1 plan during the 90-day restricted period if sales under such plan do not occur until after the expiration of the 90-day restricted period; | |
| • | net exercises of outstanding options or warrants to purchase shares of common stock, or the transfer of shares of common stock to us to satisfy tax withholding obligations pursuant equity compensation plans or arrangements maintained by us; | |
| • | the transfer of shares of common stock or securities convertible into or exchangeable or exercisable for common stock pursuant to a sale or an offer to purchase all of our outstanding common stock; | |
| • | the transfer of shares of common stock or securities convertible into or exchangeable or exercisable for common stock by gift or gifts, will or intestacy to a member or members of his or her immediate family, to at trust formed for the benefit of any such person, or to a partnership, the partners of which are exclusively that person and/or a member or members of his or her immediate family and/or a charity; or | |
| • | the transfer or distribution of shares of common stock or securities convertible into or exchangeable or exercisable for common stock by a partnership, trust, corporation, or similar entity to its partners, limited liability company members or stockholders. |
With respect to the last two bullets, it is a condition to the
transfer or distribution that the transferee execute a copy of
the lock-up
agreement, no filing by any party (donor, donee, transferor or
transferee) under Section 16(a) of the Exchange Act shall
be required or shall be made voluntarily in connection with such
transfer or distribution (other than a filing on Form 5
made after the expiration of the
90-day
restricted period), and no such transfer or distribution may
include a disposition for value.
In order to facilitate the offering of the common stock, the
underwriters may engage in transactions that stabilize, maintain
or otherwise affect the price of the common stock. Specifically,
the underwriters may sell more shares than they are obligated to
purchase under the underwriting agreement, creating a short
position. A short sale is covered if the short position is no
greater than the number of shares available for purchase by the
underwriters under the over-allotment option. The underwriters
can close out a covered short sale by exercising the
over-allotment option or purchasing shares in the open market.
In determining the source of shares to close out a covered short
sale, the underwriters will consider, among other things, the
open market price of shares compared to the price available
under the over-allotment option. The underwriters may also sell
shares in excess of the over-allotment option, creating a naked
short position. The underwriters must close out any naked short
position by purchasing shares in the open market. A naked short
position is more likely to be created if the underwriters are
concerned that there may be downward pressure on the price of
the common stock in the open market after pricing that could
adversely affect investors who purchase in the offering. In
addition, to stabilize the price of the common stock, the
underwriters may bid for, and purchase, shares of common stock
in the open market. Finally, the underwriting syndicate may
reclaim selling concessions allowed to an underwriter or a
dealer for distributing the common stock in the offering, if the
syndicate repurchases previously distributed common stock to
cover syndicate short positions or to stabilize the price of the
common stock. These activities may raise or maintain the market
price of the common stock above independent market levels or
prevent or retard a decline in the market price of the common
stock. The underwriters are not required to engage in these
activities, and may end any of these activities at any time.
S-36
Table of Contents
Our shares of common stock are listed on The NASDAQ Global
Select Market under the symbol “XNPT.”
We and the underwriters have agreed to indemnify each other
against certain liabilities, including liabilities under the
Securities Act.
Certain of the underwriters and their respective affiliates
have, from time to time, performed, and may in the future
perform, various financial advisory and investment banking
services for the company, for which they received or will
receive customary fees and expenses.
In relation to each Member State of the European Economic Area
which has implemented the Prospectus Directive (each, a Relevant
Member State), each underwriter has represented and agreed that
with effect from and including the date on which the Prospectus
Directive is implemented in that Relevant Member State (the
Relevant Implementation Date) it has not made and will not make
an offer of shares to the public in that Relevant Member State
prior to the publication of a prospectus in relation to the
shares which has been approved by the competent authority in
that Relevant Member State or, where appropriate, approved in
another Relevant Member State and notified to the competent
authority in that Relevant Member State, all in accordance with
the Prospectus Directive, except that it may, with effect from
and including the Relevant Implementation Date, make an offer of
shares to the public in that Relevant Member State at any time:
(a) to legal entities which are authorized or regulated to
operate in the financial markets or, if not so authorized or
regulated, whose corporate purpose is solely to invest in
securities;
(b) to any legal entity which has two or more of
(1) an average of at least 250 employees during the
last financial year; (2) a total balance sheet of more
than €43,000,000 and (3) an annual net turnover
of more than €50,000,000, as shown in its last annual
or consolidated accounts;
(c) to fewer than 100 natural or legal persons (other than
qualified investors as defined in the Prospectus Directive)
subject to obtaining the prior consent of the representatives
for any such offer; or
(d) in any other circumstances which do not require the
publication by the Issuer of a prospectus pursuant to
Article 3 of the Prospectus Directive.
For the purposes of this provision, the expression an
“offer of shares to the public” in relation to any
shares in any Relevant Member State means the communication in
any form and by any means of sufficient information on the terms
of the offer and the shares to be offered so as to enable an
investor to decide to purchase or subscribe the shares, as the
same may be varied in that Relevant Member State by any measure
implementing the Prospectus Directive in that Relevant Member
State and the expression Prospectus Directive means Directive
2003/71/EC and includes any relevant implementing measure in
each Relevant Member State.
Each underwriter has represented and agreed that:
(a) it has only communicated or caused to be communicated
and will only communicate or cause to be communicated an
invitation or inducement to engage in investment activity
(within the meaning of Section 21 of the FSMA) received by
it in connection with the issue or sale of the shares in
circumstances in which Section 21(1) of the FSMA does not
apply to the; and
(b) it has complied and will comply with all applicable
provisions of the FSMA with respect to anything done by it in
relation to the shares in, from or otherwise involving the
United Kingdom.
The shares may not be offered or sold by means of any document
other than (i) in circumstances which do not constitute an
offer to the public within the meaning of the Companies
Ordinance (Cap.32, Laws of Hong Kong), or (ii) to
“professional investors” within the meaning of the
Securities and Futures Ordinance (Cap.571, Laws of Hong Kong)
and any rules made thereunder, or (iii) in other
circumstances which do not result in the document being a
“prospectus” within the meaning of the Companies
Ordinance (Cap.32, Laws of Hong Kong), and no advertisement,
invitation or document relating to the shares may be issued or
may be in the possession of any person for the purpose of issue
(in each case whether in Hong Kong or elsewhere), which is
directed at, or the contents of which are likely to be accessed
or read by, the public in Hong Kong (except if permitted to do
so under the laws of Hong Kong) other than with respect to
shares which are or are intended to be disposed of only to
persons outside Hong Kong or
S-37
Table of Contents
only to “professional investors” within the meaning of
the Securities and Futures Ordinance (Cap. 571, Laws of Hong
Kong) and any rules made thereunder.
This prospectus has not been registered as a prospectus with the
Monetary Authority of Singapore. Accordingly, this prospectus
and any other document or material in connection with the offer
or sale, or invitation for subscription or purchase, of the
shares may not be circulated or distributed, nor may the shares
be offered or sold, or be made the subject of an invitation for
subscription or purchase, whether directly or indirectly, to
persons in Singapore other than (i) to an institutional
investor under Section 274 of the Securities and Futures
Act, Chapter 289 of Singapore (the “SFA”),
(ii) to a relevant person, or any person pursuant to
Section 275(1A), and in accordance with the conditions,
specified in Section 275 of the SFA or (iii) otherwise
pursuant to, and in accordance with the conditions of, any other
applicable provision of the SFA.
Where the shares are subscribed or purchased under
Section 275 by a relevant person which is: (a) a
corporation (which is not an accredited investor) the sole
business of which is to hold investments and the entire share
capital of which is owned by one or more individuals, each of
whom is an accredited investor; or (b) a trust (where the
trustee is not an accredited investor) whose sole purpose is to
hold investments and each beneficiary is an accredited investor,
shares, debentures and units of shares and debentures of that
corporation or the beneficiaries’ rights and interest in
that trust shall not be transferable for 6 months after
that corporation or that trust has acquired the shares under
Section 275 except: (1) to an institutional investor
under Section 274 of the SFA or to a relevant person, or
any person pursuant to Section 275(1A), and in accordance
with the conditions, specified in Section 275 of the SFA;
(2) where no consideration is given for the transfer; or
(3) by operation of law.
The securities have not been and will not be registered under
the Financial Instruments and Exchange Law of Japan (the
Financial Instruments and Exchange Law) and each underwriter has
agreed that it will not offer or sell any securities, directly
or indirectly, in Japan or to, or for the benefit of, any
resident of Japan (which term as used herein means any person
resident in Japan, including any corporation or other entity
organized under the laws of Japan), or to others for re-offering
or resale, directly or indirectly, in Japan or to a resident of
Japan, except pursuant to an exemption from the registration
requirements of, and otherwise in compliance with, the Financial
Instruments and Exchange Law and any other applicable laws,
regulations and ministerial guidelines of Japan.
S-38
Table of Contents
LEGAL
MATTERS
The validity of the shares of common stock offered by this
prospectus supplement will be passed upon for us by Cooley
Godward Kronish
llp, Palo Alto,
California. The underwriters are being represented by Davis
Polk & Wardwell LLP, Menlo Park, California.
EXPERTS
Ernst & Young LLP, independent registered public
accounting firm, has audited our financial statements included
in our Annual Report on
Form 10-K
for the year ended December 31, 2008, and the effectiveness
of our internal control over financial reporting as of
December 31, 2008, as set forth in their reports, which are
incorporated by reference in this prospectus supplement and
elsewhere in the registration statement of which this prospectus
supplement and the accompanying prospectus are a part. Our
financial statements are incorporated by reference in reliance
on Ernst & Young LLP’s reports, given on their
authority as experts in accounting and auditing.
WHERE YOU
CAN FIND MORE INFORMATION
This prospectus supplement and the accompanying prospectus are
part of a registration statement on
Form S-3
that we filed with the SEC under the Securities Act and do not
contain all the information set forth in the registration
statement. Whenever a reference is made in this prospectus
supplement or the accompanying prospectus to any of our
contracts, agreements or other documents, the reference may not
be complete, and you should refer to the exhibits that are a
part of the registration statement or the exhibits to the
reports or other documents incorporated by reference in this
prospectus supplement and the accompanying prospectus for a copy
of such contract, agreement or other document.
We file annual, quarterly and special reports, proxy statements
and other information with the SEC. You may read and copy any
document we file at the SEC’s Public Reference Room at
100 F Street, N.E., Washington, D.C. 20549.
Please call the SEC at
1-800-SEC-0330
for more information about the operation of the public reference
room. The SEC also maintains an Internet site that contains
reports, proxy and information statements and other information
regarding issuers that file electronically with the SEC,
including XenoPort. The SEC’s Internet site can be found at
http://www.sec.gov.
The SEC allows us to incorporate by reference the information we
file with it, which means that we can disclose important
information to you by referring you to another document that we
have filed separately with the SEC. You should read the
information incorporated by reference because it is an important
part of this prospectus supplement and the accompanying
prospectus. We incorporate by reference the following
information or documents that we have filed with the SEC
(Commission File
No. 0-51329):
| • | our Current Report on Form 8-K, filed with the SEC on January 13, 2009; | |
| • | our Current Report on Form 8-K, filed with the SEC on January 16, 2009; | |
| • | our Current Report on Form 8-K, filed with the SEC on February 2, 2009; | |
| • | our Annual Report on Form 10-K for the fiscal year ended December 31, 2008, filed with the SEC on February 26, 2009 (the “2008 Form 10-K”); | |
| • | our Current Report on Form 8-K, filed with the SEC on March 3, 2009; | |
| • | our Current Report on Form 8-K, filed with the SEC on March 16, 2009; | |
| • | our Current Report on Form 8-K, filed with the SEC on April 1, 2009; | |
| • | the information specifically incorporated by reference into our 2008 Form 10-K from our definitive proxy statement on Schedule 14A, filed with the SEC on April 9, 2009; | |
| • | our Current Report on Form 8-K, filed with the SEC on April 13, 2009; |
S-39
Table of Contents
| • | our Current Report on Form 8-K, filed with the SEC on April 27, 2009; | |
| • | our Quarterly Report on Form 10-Q for the quarter ended March 31, 2009, filed with the SEC on May 7, 2009; | |
| • | our Current Report on Form 8-K, filed with the SEC on June 30, 2009; and | |
| • | the description of our common stock set forth in our registration statement on Form 8-A, filed with the SEC on May 25, 2005, as amended by Form 8-A/A, filed with the SEC on December 20, 2005, including any further amendments thereto or reports filed for the purposes of updating this description. |
Any information in any of the foregoing documents will
automatically be deemed to be modified or superseded to the
extent that information in this prospectus supplement or in a
later filed document that is incorporated or deemed to be
incorporated herein by reference modifies or replaces such
information.
We also incorporate by reference any future filings (other than
current reports furnished under Item 2.02 or Item 7.01
of
Form 8-K
and exhibits filed on such form that are related to such items)
made with the SEC pursuant to Sections 13(a), 13(c), 14 or
15(d) of the Securities Exchange Act of 1934, as amended, after
the date of this prospectus supplement and prior to the
termination of the offering of the common stock covered by this
prospectus supplement. Information in such future filings
updates and supplements the information provided in this
prospectus supplement. Any statements in any such future filings
will automatically be deemed to modify and supersede any
information in any document we previously filed with the SEC
that is incorporated or deemed to be incorporated herein by
reference to the extent that statements in the later filed
document modify or replace such earlier statements.
We will furnish without charge to you, upon written or oral
request, a copy of any or all of the documents incorporated by
reference, including exhibits to these documents. You should
direct any requests for documents to XenoPort, Inc., Attention:
Investor Relations, 3410 Central Expressway, Santa Clara,
California 95051. Our phone number is (408) 616-7200.
S-40
Table of Contents
PROSPECTUS
XenoPort,
Inc.
Common
Stock
Warrants to Purchase Common Stock
Units
Warrants to Purchase Common Stock
Units
From time to time, we may offer and sell any combination of the
securities described in this prospectus in amounts, either
individually or in units, at prices and on terms described in
one or more supplements to this prospectus.
This prospectus describes some of the general terms that may
apply to an offering of our securities. The specific terms and
any other information relating to a specific offering will be
set forth in a post-effective amendment to the registration
statement of which this prospectus is a part or in a supplement
to this prospectus, or may be set forth in one or more documents
incorporated by reference in this prospectus. We may also
authorize one or more free writing prospectuses to be provided
to you in connection with a specific offering. You should read
this prospectus, the applicable prospectus supplement and any
free writing prospectuses we have authorized for use in
connection with a specific offering, as well as any documents
incorporated by reference in this prospectus and the applicable
prospectus supplement, carefully before you invest.
We may offer and sell these securities to or through one or more
underwriters, dealers and agents, or directly to purchasers, on
a continuous or delayed basis. The supplements to this
prospectus will provide the specific terms of the plan of
distribution. The net proceeds we expect to receive from sales
by us will be set forth in the applicable prospectus supplement.
Our common stock is listed on the NASDAQ Global Select Market
under the trading symbol “XNPT.” On December 29,
2008, the last reported sale price of our common stock on the
NASDAQ Global Select Market was $21.60 per share.
Investing in our securities involves a high degree of risk.
You should review carefully the risks and uncertainties
described under the heading “Risk Factors” contained
in any applicable prospectus supplement and in any free writing
prospectuses we have authorized for use in connection with a
specific offering, and under similar headings in the other
documents that are incorporated by reference into this
prospectus.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these
securities or determined if this prospectus is truthful or
complete. Any representation to the contrary is a criminal
offense.
The date of this prospectus is December 30, 2008
TABLE OF
CONTENTS
| Page | ||||
| 2 | ||||
| 3 | ||||
| 3 | ||||
| 4 | ||||
| 4 | ||||
| 7 | ||||
| 9 | ||||
| 10 | ||||
| 10 | ||||
| 10 | ||||
ABOUT
THIS PROSPECTUS
This prospectus is part of a registration statement on
Form S-3
that we filed with the Securities and Exchange Commission, or
the SEC, using the “shelf” registration process. By
using a shelf registration statement, we may offer and sell from
time to time in one or more offerings the securities described
in this prospectus, either individually or in units. No limit
exists on the aggregate number of shares of common stock
and/or
warrants to purchase common stock that we may sell pursuant to
the registration statement.
You should rely only on the information contained in, or
incorporated by reference into, this prospectus or any
applicable prospectus supplement, along with the information
contained in any free writing prospectuses we have authorized
for use in connection with a specific offering. We have not
authorized anyone to provide you with different information.
This document may only be used where it is legal to sell these
securities. You should not assume that the information contained
in this prospectus, in any applicable prospectus supplement or
in any free writing prospectuses we have authorized for use in
connection with a specific offering is accurate as of any date
other than its respective date, regardless of when this
prospectus, any prospectus supplement or any free writing
prospectus we have authorized for use in connection with a
specific offering is delivered, or when any sale of our
securities occurs. If there is any inconsistency between the
information in this prospectus and a prospectus supplement, you
should rely on the information in the prospectus supplement.
This prospectus and the information incorporated herein by
reference include trademarks, service marks and trade names
owned by us or others. All trademarks, service marks and trade
names included or incorporated by reference into this prospectus
or any applicable prospectus supplement are the property of
their respective owners.
We urge you to read carefully this prospectus, any applicable
prospectus supplement and any free writing prospectuses we have
authorized for use in connection with a specific offering,
together with the information incorporated herein by reference
as described under the heading “Where You Can Find More
Information,” before deciding whether to invest in any of
the securities being offered.
References in this prospectus to “XenoPort”,
“we”, “us” and “our” refer to
XenoPort, Inc., a Delaware corporation. Our principal executive
offices are located at 3410 Central Expressway,
Santa Clara, CA 95051, and our telephone number is
(408) 616-7200.
Our web site address is
http://www.xenoport.com.
Information found on, or accessible through, our website is not
a part of, and is not incorporated into, this prospectus.
2
Table of Contents
RISK
FACTORS
Investing in our securities involves a high degree of risk. You
should carefully consider the risk factors identified in any
applicable prospectus supplement and in any free writing
prospectuses we have authorized for use in connection with a
specific offering, as well as in our most recent annual and
quarterly filings with the SEC in addition to the other
information contained in this prospectus, any applicable
prospectus supplement, the documents incorporated by reference
herein or therein, and in any free writing prospectuses we have
authorized for use in connection with a specific offering,
before deciding whether to purchase any of our securities. Each
of the risk factors could adversely affect our business,
operating results and financial condition, as well as adversely
affect the value of an investment in our securities, and you may
lose all or part of your investment.
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus and the documents incorporated by reference
contain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as
amended. These statements are based on our our current
expectations, assumptions, estimates and projections about our
business and our industry. Discussions containing these
forward-looking statements may be found, among other places, in
“Business,” “Risk Factors” and
“Management’s Discussion and Analysis of Financial
Condition and Results of Operations” incorporated by
reference from our most recent annual report on
Form 10-K
and in our most recent quarterly report on
Form 10-Q,
as well as any amendments thereto reflected in subsequent
filings with the SEC. Forward-looking statements include, but
are not limited to, statements about:
| • | our ability to obtain and maintain regulatory approvals for our product candidates; | |
| • | our expectations with respect to potential commercialization of any of our product candidates; | |
| • | the success and timing of our preclinical studies and clinical trials; | |
| • | our plans to research, develop and commercialize our product candidates; | |
| • | the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing, and our ability to obtain additional financing; and | |
| • | our ability to obtain and maintain intellectual property protection for our product candidates. |
In some cases, you can identify forward-looking statements by
terms such as “anticipate,” “believe,”
“could,” “estimate,” “expect,”
“intend,” “may,” “plan,”
“potential,” “predict,” “project,”
“should,” “will,” “would” and
similar expressions intended to identify forward-looking
statements. These statements involve known and unknown risks,
uncertainties and other factors that may cause our actual
results, levels of activity, performance, time frames or
achievements to be materially different from the information
expressed or implied by these forward-looking statements. While
we believe that we have a reasonable basis for each
forward-looking statement, we caution you that these statements
are based on a combination of facts and factors currently known
by us and our projections of the future, about which we cannot
be certain. We discuss many of these risks, uncertainties and
other factors in greater detail under the heading “Risk
Factors” contained in any applicable prospectus supplement,
in any free writing prospectuses we have authorized for use in
connection with a specific offering, and in our most recent
annual report on
Form 10-K
and in our most recent quarterly report on
Form 10-Q,
as well as any amendments thereto reflected in subsequent
filings with the SEC. Given these risks, uncertainties and other
factors, you should not place undue reliance on these
forward-looking statements. Also, these forward-looking
statements represent our estimates and assumptions only as of
the date such forward-looking statements are made. You should
read carefully this prospectus, any applicable prospectus
supplement and any free writing prospectuses we have authorized
for use in connection with a specific offering, together with
the information incorporated herein by reference as described
under the heading “Where You Can Find More
Information,” completely and with the understanding that
our actual future results may be materially different from what
we expect. We hereby qualify all of our forward-looking
statements by these cautionary statements.
3
Table of Contents
Except as required by law, we assume no obligation to update
these forward-looking statements publicly, or to update the
reasons actual results could differ materially from those
anticipated in these forward-looking statements, even if new
information becomes available in the future.
USE OF
PROCEEDS
Except as described in any prospectus supplement or in any free
writing prospectuses we have authorized for use in connection
with a specific offering, we anticipate using the net proceeds
to us from the sale of our securities for general corporate
purposes, including clinical trial, research and development,
general and administrative and manufacturing expenses. We may
also use a portion of the net proceeds for the potential
acquisition of, or investment in, businesses, products and
technologies that are complementary to our own, although we are
not currently planning or negotiating any such transactions.
Pending these uses, we intend to invest the net proceeds in
investment-grade, interest-bearing securities.
DESCRIPTION
OF CAPITAL STOCK
Our authorized capital stock consists of 60,000,000 shares
of common stock, par value $.001 per share, and
5,000,000 shares of preferred stock, par value $.001 per
share. As of September 30, 2008, there were
25,255,460 shares of common stock issued and outstanding
and no shares of preferred stock issued and outstanding. We may
issue shares of our common stock from time to time in one or
more offerings. We will set forth in the applicable prospectus
supplement a description of the terms of the offering of common
stock, including the offering price, the net proceeds to us and
other offering material relating to such offering.
The following summary description of our common and preferred
stock is based on the provisions of our amended and restated
certificate of incorporation, amended and restated bylaws and
the applicable provisions of the Delaware General Corporation
Law. This information may not be complete in all respects and is
qualified entirely by reference to the provisions of our amended
and restated certificate of incorporation and bylaws and the
Delaware General Corporation Law. For information on how to
obtain copies of our amended and restated certificate of
incorporation and amended and restated bylaws, which are
exhibits to the registration statement of which this prospectus
forms a part, see “Where You Can Find More
Information.”
Common
Stock
The holders of our common stock are entitled to one vote for
each share held of record on all matters submitted to a vote of
the stockholders and do not currently have cumulative voting
rights. Accordingly, holders of a majority of the shares of
common stock entitled to vote in any election of directors may
elect all of the directors standing for election. However,
holders of our common stock may not, unless otherwise required
by law, vote on any amendment to our amended and restated
certificate of incorporation that relates solely to the terms of
one or more series of preferred stock that we may issue if the
holders of such preferred stock are entitled to vote on such
amendment. Subject to preferences that may be applicable to any
outstanding shares of preferred stock, the holders of common
stock are entitled to receive ratably those dividends, if any,
as may be declared by the board of directors out of legally
available funds. In the event of our liquidation, dissolution or
winding up, holders of our common stock are entitled to share
ratably in the net assets legally available for distribution to
stockholders after the payment of all of our debts and other
liabilities and the satisfaction of any liquidation preference
granted to the holders of any then outstanding shares of
preferred stock. Holders of our common stock have no preemptive,
conversion or subscription rights, and there are no redemption
or sinking fund provisions applicable to the common stock. The
rights, preferences and privileges of the holders of our common
stock are subject to, and may be adversely affected by, the
rights of the holders of shares of any series of preferred stock
that we may designate in the future. All of our outstanding
shares of common stock are, and the shares of common stock
offered under this prospectus and applicable prospectus
supplements will be, fully paid and nonassessable.
4
Table of Contents
Preferred
Stock
Our amended and restated certificate of incorporation provides
that our board of directors has the authority, without further
action by our stockholders, to issue up to 5,000,000 shares
of preferred stock, of which 1,000,000 shares are
authorized for issuance as Series A junior participating
preferred stock, none of which are outstanding. Our board of
directors may issue preferred stock in one or more series and
has the authority to establish from time to time the number of
shares to be included in each such series, to fix the rights,
preferences and privileges of the shares of each wholly unissued
series and any qualifications, limitations or restrictions
thereon, and to increase or decrease the number of shares of any
such series, but not below the number of shares of such series
then outstanding. Our board of directors may authorize the
issuance of preferred stock with voting or conversion rights
that could adversely affect the voting power or other rights of
the holders of our common stock. The issuance of preferred
stock, while providing flexibility in connection with possible
acquisitions and other corporate purposes, could, among other
things, have the effect of delaying, deferring or preventing a
change in control of us and may adversely affect the market
price of our common stock and the voting and other rights of the
holders of our common stock.
Stock
Options and Restricted Stock Unit Awards
As of September 30, 2008, there were 3,322,422 shares
of our common stock issuable upon the exercise of outstanding
stock options, having a weighted-average exercise price of
$27.48 per share, and 218,315 shares of our common stock
issuable upon the vesting of outstanding restricted stock unit
awards. As of September 30, 2008, an aggregate of
2,024,510 shares of our common stock were reserved for
future issuance under our 2005 Equity Incentive Plan, our 2005
Non-Employee Directors’ Stock Option Plan and our 2005
Employee Stock Purchase Plan.
Warrants
As of September 30, 2008, warrants to purchase a total of
21,332 shares of our common stock at an exercise price of
$15.00 per share were outstanding. Each warrant contains
provisions for the adjustment of the exercise price and the
number of shares issuable upon the exercise of the warrant in
the event of certain stock dividends, stock splits,
reorganizations, reclassifications and consolidations.
Registration
Rights
As of September 30, 2008, the holders of up to
1,727,157 shares of our common stock or their transferees,
may require us, on not more than two occasions, to file and
cause to be declared effective a registration statement under
the Securities Act with respect to their shares of common stock
if the aggregate offering price of such shares, net of
underwriting discounts and commissions, is expected to exceed
$10,000,000. In such event, we will be required to use our
commercially reasonable efforts to effect the registration.
Further, if we are then qualified to file a registration
statement on
Form S-3,
these holders may require us to file a registration statement on
Form S-3
so long as the aggregate offering price of the shares to be sold
under the registration statement on
Form S-3,
net of underwriting discounts and commissions, is at least
$1,000,000; however, we are only obligated to effect one
registration statement on
Form S-3
in any
12-month
period. In addition, if we propose to register any of our
securities under the Securities Act either for our own account
or for the account of other stockholders, these security holders
are entitled to notice of the registration and will be entitled
to include their shares of common stock in the registration
statement. These registration rights are subject to specified
conditions and limitations, including the right of the
underwriters to limit the number of shares included in any such
registration under certain circumstances. We will pay all
expenses relating to any demand,
Form S-3
or piggyback registration, other than underwriting discounts and
commissions. These registration rights and our obligations will
terminate upon the earlier of four years following the closing
of our initial public offering, which date is June 7, 2009,
or, as to a given holder of these registration rights who owns
less than 5% of our outstanding common stock, when such holder
can sell all of such holder’s common stock that carries
registration rights in a
90-day
period pursuant to Rule 144 promulgated under the
Securities Act.
5
Table of Contents
Delaware
Anti-Takeover Law and Certain Provisions of Our Certificate of
Incorporation and Bylaws
Delaware
Law
We are governed by Section 203 of the Delaware General
Corporation Law. In general, Section 203 prohibits a public
Delaware corporation from engaging in a “business
combination” with an “interested stockholder” for
a period of three years after the date of the transaction in
which the person became an interested stockholder, unless the
business combination is approved in a prescribed manner. A
“business combination” includes mergers, asset sales
or other transactions resulting in a financial benefit to the
interested stockholder. An “interested stockholder” is
a person who, together with affiliates and associates, owns, or
within three years, did own, 15% or more of the
corporation’s outstanding voting stock. These provisions
may have the effect of delaying, deferring or preventing a
change in our control.
Certificate
of Incorporation and Bylaw Provisions
Our amended and restated certificate of incorporation and
amended and restated bylaws provide that our board of directors
shall be divided into three classes of directors, with each
class serving a staggered three-year term. The classification
system of electing directors may tend to discourage a third
party from making a tender offer or otherwise attempting to
obtain control of us and may maintain the composition of our
current board of directors, as the classification of the board
of directors generally increases the difficulty of replacing a
majority of directors. In addition, our amended and restated
certificate of incorporation:
| • | provides that any action required or permitted to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by any consent in writing; | |
| • | provides that the authorized number of directors may be changed only by resolution of the board of directors; and | |
| • | eliminates cumulative voting for the election of directors (unless at the time of any such election we are subject to certain provisions of the California General Corporation Law). |
Our amended and restated bylaws also provide that special
meetings of our stockholders may be called only by the
chairperson of our board of directors, our chief executive
officer or by our board of directors pursuant to a resolution
adopted by a majority of the total number of authorized
directors.
These and other provisions contained in our amended and restated
certificate of incorporation and amended and restated bylaws
could delay or discourage some types of transactions involving
an actual or potential change in our control or change in our
management, including transactions in which stockholders might
otherwise receive a premium for their shares over then current
prices, and may limit the ability of our stockholders to remove
current management or approve transactions that our stockholders
may deem to be in their best interests and, therefore, could
adversely affect the price of our common stock.
Stockholder
Rights Plan; Series A Junior Participating Preferred
Stock
In December 2005, our board of directors adopted a Stockholder
Rights Plan, pursuant to which all stockholders of record as of
January 13, 2006 received rights to purchase shares of a
newly created series of preferred stock. Each right entitles the
registered holder to purchase from us one one-hundredth of a
share of Series A junior participating preferred stock at
an exercise price of $140.00 per right, subject to adjustment.
The rights trade with our common stock and are not currently
exercisable. The rights will become exercisable when a person or
group acquires 15% or more of our outstanding common stock or
ten business days after commencement or announcement of a tender
or exchange offer for 15% or more of our outstanding common
stock. If a person or group acquires 15% or more of our
outstanding common stock, all rights holders except such buyer
will be entitled to acquire our common stock at a discount. In
the event that we are acquired in a merger or other business
combination transaction or 50% or more of our consolidated
assets or earning power are sold to a person or group who has
acquired 15% or more of our outstanding common stock, proper
provision will be made so that each such holder of a right will
thereafter have the right to receive, upon the exercise of the
right, shares of common stock of
6
Table of Contents
the acquiring company which at the time of such transaction will
have a market value of two times the exercise price of the right.
Each share of Series A junior participating preferred stock
will be entitled to a minimum preferential quarterly dividend
payment of $1.00 but will be entitled to an aggregate dividend
of 100 times the dividend declared per share of common stock. In
the event of liquidation, the holders of shares of Series A
junior participating preferred stock would be entitled to
receive a minimum preferential liquidation payment of $100 per
share, but would be entitled to an aggregate payment of 100
times the payment made per share of common stock. In the event
of any merger, consolidation or other transaction in which our
common stock is exchanged, each share of Series A junior
participating preferred stock would be entitled to receive 100
times the amount of consideration received per share of common
stock. Each share of Series A junior participating
preferred stock will have 100 votes, voting together with the
shares of common stock. The shares of Series A junior
participating preferred stock that we may issue rank junior to
any other series of our preferred stock. The Series A
junior participating preferred stock is not convertible or
redeemable and has no preemptive, subscription or conversion
rights.
Our board of directors may terminate the Stockholder Rights Plan
at any time, amend the Stockholder Rights Plan without the
approval of any holders of the rights or redeem the rights prior
to the time a person or group acquires 15% or more of our common
stock. The rights are protected by customary anti-dilution
provisions. These rights will expire on January 13, 2016,
unless the rights are earlier redeemed or exchanged by us. The
rights have certain anti-takeover effects and will cause
substantial dilution to a person or group that attempts to
acquire us on terms not approved by our board of directors.
Transfer
Agent and Registrar
The Transfer Agent and Registrar for our common stock is BNY
Mellon Shareowner Services. The transfer agent’s address is
480 Washington Boulevard, Jersey City, New Jersey 07310.
DESCRIPTION
OF WARRANTS
The following description, together with the additional
information we may include in any applicable prospectus
supplements and free writing prospectuses, summarizes the
material terms and provisions of the warrants to purchase common
stock that we may offer under this prospectus and may be issued
in one or more series. Warrants may be offered independently or
together with common stock offered by any prospectus supplement,
and may be attached to, or separate from, those securities.
While the terms we have summarized below will apply generally to
any warrants that we may offer under this prospectus, we will
describe the particular terms of any series of warrants that we
may offer in more detail in the applicable prospectus supplement
and any applicable free writing prospectus. The terms of any
warrants offered under a prospectus supplement may differ from
the terms described below. However, no prospectus supplement
will fundamentally change the terms that are set forth in this
prospectus or offer a security that is not registered and
described in this prospectus at the time of its effectiveness.
We will file as exhibits to the registration statement of which
this prospectus is a part, or will incorporate by reference from
a current report on
Form 8-K
that we file with the SEC, the form of warrant agreement,
including a form of warrant certificate, if applicable, that
describes the terms of the particular series of warrants we are
offering before the issuance of the related series of warrants.
The following summaries of material provisions of the warrants
and the warrant agreements are subject to, and qualified in
their entirety by reference to, all the provisions of the
warrant agreement and warrant certificate applicable to a
particular series of warrants. We urge you to read the
applicable prospectus supplement and any applicable free writing
prospectus related to the particular series of warrants that we
sell under this prospectus, as well as the complete warrant
agreements and warrant certificates that contain the terms of
the warrants.
7
Table of Contents
General
We will describe in the applicable prospectus supplement the
terms relating to a series of warrants, including:
| • | the offering price and aggregate number of warrants offered; | |
| • | the currency for which the warrants may be purchased; | |
| • | if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security; | |
| • | if applicable, the date on and after which the warrants and the related securities will be separately transferable; | |
| • | the number of shares of common stock purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise; | |
| • | the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants; | |
| • | the terms of any rights to redeem or call the warrants; | |
| • | any provisions for changes to, or adjustments in, the exercise price or number of securities issuable upon exercise of the warrants; | |
| • | the dates on which the right to exercise the warrants will commence and expire; | |
| • | the manner in which the warrant agreements and warrants may be modified; | |
| • | U.S. federal income tax consequences of holding or exercising the warrants; | |
| • | the terms of the securities issuable upon exercise of the warrants; and | |
| • | any other specific terms, preferences, rights or limitations of or restrictions on the warrants. |
Before exercising their warrants, holders of warrants will not
have any of the rights of holders of the securities purchasable
upon such exercise, including, in the case of warrants to
purchase common stock, the right to receive dividends, if any,
or, payments upon our liquidation, dissolution or winding up or
to exercise voting rights, if any.
Exercise
of Warrants
Each warrant will entitle the holder to purchase the securities
that we specify in the applicable prospectus supplement at the
exercise price that we describe in the applicable prospectus
supplement. Unless we otherwise specify in the applicable
prospectus supplement, holders of the warrants may exercise the
warrants at any time up to the specified time on the expiration
date that we set forth in the applicable prospectus supplement.
After the close of business on the expiration date, unexercised
warrants will become void.
Holders of the warrants may exercise the warrants by delivering
the warrant certificate representing the warrants to be
exercised together with specified information, and paying the
required amount in immediately available funds, as provided in
the applicable prospectus supplement. We will set forth on the
reverse side of the warrant certificate and in the applicable
prospectus supplement the information that the holder of the
warrant will be required to deliver in connection with the
warrant exercise.
Upon receipt of the required payment and the warrant certificate
properly completed and duly executed at the corporate trust
office of the warrant agent or any other office indicated in the
applicable prospectus supplement, we will issue and deliver the
securities purchasable upon such exercise. If fewer than all of
the warrants represented by the warrant certificate are
exercised, then we will issue a new warrant certificate for the
remaining amount of warrants. If we so indicate in the
applicable prospectus supplement, holders of the warrants may
surrender securities as all or part of the exercise price for
warrants.
8
Table of Contents
DESCRIPTION
OF UNITS
The following description, together with the additional
information we may include in any applicable prospectus
supplements, summarizes the material terms and provisions of the
units that we may offer under this prospectus. While the terms
we have summarized below will apply generally to any units that
we may offer under this prospectus, we will describe the
particular terms of any series of units in more detail in the
applicable prospectus supplement. The terms of any units offered
under a prospectus supplement may differ from the terms
described below. However, no prospectus supplement will
fundamentally change the terms that are set forth in this
prospectus or offer a security that is not registered and
described in this prospectus at the time of its effectiveness.
We will file as exhibits to the registration statement of which
this prospectus is a part, or will incorporate by reference from
a current report on
Form 8-K
that we file with the SEC, the form of unit agreement that
describes the terms of the series of units we are offering, and
any supplemental agreements, before the issuance of the related
series of units. The following summaries of material terms and
provisions of the units are subject to, and qualified in their
entirety by reference to, all the provisions of the unit
agreement and any supplemental agreements applicable to a
particular series of units. We urge you to read the applicable
prospectus supplements related to the particular series of units
that we sell under this prospectus, as well as the complete unit
agreement and any supplemental agreements that contain the terms
of the units.
General
We may issue units comprised of one or more shares of common
stock and warrants in any combination. Each unit will be issued
so that the holder of the unit is also the holder of each
security included in the unit. Thus, the holder of a unit will
have the rights and obligations of a holder of each included
security. The unit agreement under which a unit is issued may
provide that the securities included in the unit may not be held
or transferred separately, at any time or at any time before a
specified date.
We will describe in the applicable prospectus supplement the
terms of the series of units, including:
| • | the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately; | |
| • | any provisions of the governing unit agreement that differ from those described below; and | |
| • | any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units. |
The provisions described in this section, as well as those
described under “Description of Capital Stock” and
“Description of Warrants” will apply to each unit and
to any common stock or warrant included in each unit,
respectively.
Issuance
in Series
We may issue units in such amounts and in numerous distinct
series as we determine.
Enforceability
of Rights by Holders of Units
Each unit agent, if any, will act solely as our agent under the
applicable unit agreement and will not assume any obligation or
relationship of agency or trust with any holder of any unit. A
single bank or trust company may act as unit agent for more than
one series of units. A unit agent will have no duty or
responsibility in case of any default by us under the applicable
unit agreement or unit, including any duty or responsibility to
initiate any proceedings at law or otherwise, or to make any
demand upon us. Any holder of a unit may, without the consent of
the related unit agent or the holder of any other unit, enforce
by appropriate legal action its rights as holder under any
security included in the unit.
9
Table of Contents
Title
We, the unit agents and any of their agents may treat the
registered holder of any unit certificate as an absolute owner
of the units evidenced by that certificate for any purpose and
as the person entitled to exercise the rights attaching to the
units so requested, despite any notice to the contrary.
VALIDITY
OF CAPITAL STOCK
Cooley Godward Kronish LLP, Palo Alto, California will pass for
us upon the validity of the securities being offered by this
prospectus and applicable prospectus supplement, and counsel
named in the applicable prospectus supplement will pass upon
legal matters for any underwriters, dealers or agents.
EXPERTS
Ernst & Young LLP, independent registered public
accounting firm, has audited our financial statements included
in our Annual Report on
Form 10-K
for the year ended December 31, 2007, and the effectiveness
of our internal control over financial reporting as of
December 31, 2007, as set forth in their reports, which are
incorporated by reference in this prospectus and elsewhere in
the registration statement of which this prospectus is a part.
Our financial statements are incorporated by reference in
reliance on Ernst & Young LLP’s reports, given on
their authority as experts in accounting and auditing.
WHERE YOU
CAN FIND MORE INFORMATION
We file annual, quarterly and special reports, proxy statements
and other information with the SEC. You may read and copy any
document we file at the SEC’s Public Reference Room at
100 F Street, N.E., Washington, D.C. 20549.
Please call the SEC at
1-800-SEC-0330
for more information about the operation of the public reference
room. The SEC also maintains an Internet site that contains
reports, proxy and information statements and other information
regarding issuers that file electronically with the SEC,
including XenoPort. The SEC’s Internet site can be found at
http://www.sec.gov.
The SEC allows us to incorporate by reference the information we
file with it, which means that we can disclose important
information to you by referring you to another document that we
have filed separately with the SEC. You should read the
information incorporated by reference because it is an important
part of this prospectus. We incorporate by reference the
following information or documents that we have filed with the
SEC (Commission File
No. 0-51329):
| • | our Current Report on Form 8-K, filed with the SEC on January 15, 2008, as amended by Form 8-K/A, filed with the SEC on January 16, 2008; | |
| • | our Current Report on Form 8-K, filed with the SEC on February 1, 2008; | |
| • | our Annual Report on Form 10-K for the fiscal year ended December 31, 2007, filed with the SEC on February 22, 2008 (the “2007 Form 10-K”); | |
| • | our Current Report on Form 8-K, filed with the SEC on February 28, 2008; | |
| • | our Current Report on Form 8-K, filed with the SEC on March 5, 2008; | |
| • | the information specifically incorporated by reference into our 2007 Form 10-K from our definitive proxy statement on Schedule 14A, filed with the SEC on April 8, 2008; | |
| • | our Quarterly Report on Form 10-Q for the quarter ended March 31, 2008, filed with the SEC on May 8, 2008; | |
| • | our Current Report on Form 8-K, filed with the SEC on July 18, 2008; | |
| • | our Current Report on Form 8-K, filed with the SEC on August 1, 2008; |
10
Table of Contents
| • | our Quarterly Report on Form 10-Q for the quarter ended June 30, 2008, filed with the SEC on August 7, 2008; | |
| • | our Current Report on Form 8-K, filed with the SEC on September 16, 2008; | |
| • | our Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, filed with the SEC on November 6, 2008; | |
| • | our Current Report on Form 8-K, filed with the SEC on November 10, 2008; | |
| • | our Current Report on Form 8-K, filed with the SEC on December 2, 2008; | |
| • | our Current Report on Form 8-K, filed with the SEC on December 30, 2008; and | |
| • | the description of our common stock set forth in our registration statement on Form 8-A, filed with the SEC on May 25, 2005, as amended by Form 8-A/A, filed with the SEC on December 20, 2005, including any further amendments thereto or reports filed for the purposes of updating this description. |
Any information in any of the foregoing documents will
automatically be deemed to be modified or superseded to the
extent that information in this prospectus or in a later filed
document that is incorporated or deemed to be incorporated
herein by reference modifies or replaces such information.
We also incorporate by reference any future filings (other than
current reports furnished under Item 2.02 or Item 7.01
of
Form 8-K
and exhibits filed on such form that are related to such items)
made with the SEC pursuant to Sections 13(a), 13(c), 14 or
15(d) of the Securities Exchange Act of 1934, as amended, until
we file a post-effective amendment that indicates the
termination of the offering of the securities made by this
prospectus. Information in such future filings updates and
supplements the information provided in this prospectus. Any
statements in any such future filings will automatically be
deemed to modify and supersede any information in any document
we previously filed with the SEC that is incorporated or deemed
to be incorporated herein by reference to the extent that
statements in the later filed document modify or replace such
earlier statements.
We will furnish without charge to you, upon written or oral
request, a copy of any or all of the documents incorporated by
reference, including exhibits to these documents. You should
direct any requests for documents to XenoPort, Inc., Attention:
Investor Relations, 3410 Central Expressway, Santa Clara,
California 95051. Our phone number is
(408) 616-7200.
11